Advanced Diagnostics

P 1 **A New Point of Care Testing (POCT) for Respiratory Pathogen Detection: Comparison of the Hysen POCT Analyzer with Conventional RT-PCR**
G. Garzillo[1], C. Fraccalvieri[1], M. Lucente[1], B. Galano[1], M. Ferraris[1], G. Guarona[2], S. Ferrari[1], V. Chessa[1], R. Qosja[1], A. Orsi[2]
[1]U.O. Igiene, IRCCS AOM- Azienda Ospedaliera Metropolitana, Genova, Italy, [2]Dipartimento di Scienze della Salute (DiSSal), Università di Genova, Italy

P 2 **Anal HPV Screening in PLWH: Self-Sampling Concordance and Optimization of Invalid Results**
G.B. Tassone[1], M.A. Zingaropoli[2], Xh. Xhuli[1], E.N. Cavallari[1], E. Coratti[1], M. Bernassola[2], D.M. Rodio[2], L. Santinelli[1], S. Fontana[1], G. d'Ettorre[1], G. Antonelli[2], O. Turriziani[2]
[1]Sapienza University of Rome, Rome, Italy, [2]Policlinico Umberto I, Sapienza University of Rome, Rome, Italy

P 3 **Evaluation of Whole Genome Sequencing of HIV-1 Proviral DNA (WGS-DNA) for Drug Resistance Testing**
F. Stefanelli[1], N. Randazzo[1], N. Nigro[1], M. Lucente[1], G. Garzillo[1], M. Ferraris[1], V. Chessa[1], R. Qosja[1], L. Taramasso[1], V. Ricucci[1], B. Bruzzone[1]
[1]IRCCS Azienda Ospedaliera Metropolitana San Martino Hospital, Genoa, Italy, [2]University of Genoa, Genoa, Italy

P 4 **Interpretative Challenges of Respiratory Syndromic Panels: Age-Related Prevalence, Co-detection, and Cycle Thresholds**
M.A. Zingaropoli[1], G.B. Tassone[2], E. Coratti[2], D.M. Rodio[1], M. Bernassola[1], R. Campagna[2], L. Caivano[2], F. Pulcinelli[3], F. Midulla[3], G. Galardo[4], A. Pierangeli[2], G. Antonelli[2], O. Turriziani[2]
[1]Microbiology and Virology Unit, Policlinico Umberto I, Sapienza University of Rome, Italy, [2]Department of Molecular Medicine, Sapienza University of Rome, Italy, [3]Department of Pediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, Italy, [4]Department of Medical and Cardiovascular Sciences, Sapienza University of Rome, Italy

P 5 **Performance of HIV-1 Whole-Genome Sequencing in HIV-RNA positive plasma samples**
A. Callegaro[1], M. Mazzoni[1], S. Uceda Renteria[1], G. Bozzi[2], A. Parisi[1], V. Castelli[2], B. Mariani[2], A. Muscatello[2], A. Bandera[2,3], C. Alteri[1,4]
[1]Microbiology and Virology Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [2]Infectious Diseases Unit, IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [3]Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, [4]Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy

P 6 **Persistent atypical HIV-1 viremia detected exclusively via the pol target using a dual-target (pol and LTR) assay: a case report highlighting a novel diagnostic challenge**
A. Amendola, S. Belladonna, F. Smoquina, G. Capecchi, V. Mazzotta, M.G. Bocci, F. Maggi, F. Forbici, L. Fabeni
National Institute for Infectious Diseases (INMI) "Lazzaro Spallanzani" IRCCS, Rome, Italy

P 7 **Sometimes less is more: Impact of input volume on HIV-1 proviral DNA Whole-Genome Sequencing**
F. Stefanelli[1], N. Randazzo[1], N. Nigro[1], G. Garzillo[1], G. Guarona[2], S. Ferrari[1], S. Varesano[1], M. Giurco[2], A. Di Biagio[1,2], L. Taramasso[1], B. Bruzzone[1]
[1]IRCCS Azienda Ospedaliera Metropolitana San Martino Hospital, Genoa, Italy, [2]University of Genoa, Genoa, Italy

P 8 **The future is now: HIV-1 Whole Genome Sequencing for comprehensive Drug Resistance Testing**
F. Stefanelli[1], N. Randazzo[1], N. Nigro[1] , M. Lucente[1], C. Fraccalvieri[1], B. Giusto[1], G. Cologgi[2], L. Taramasso[1], A. Di Biagio[1,2], B. Bruzzone[1]
[1]IRCCS Azienda Ospedaliera Metropolitana San Martino Hospital, Genoa, Italy, [2]University of Genoa, Genoa, Italy

Ageing and HIV

P 9 **Aging and nortality among people with diagnosed HIV in Italy: recent trends and projections**
A. Viguerie[1], V. Regine[2], L. Pugliese[2], B. Suligoi[2]
[1]University of Urbino, Urbino, Italy, [2]Italian National Institute of Health, Rome Italy

P 10 **BIC/FTC/TAF in People with HIV Aged ≥50 Years: A 24-Month Real-World Analysis**
G. Moi[1], A. De Vito[1], S. Spampinato[2], D. Bivona[2], S. Daqduqi[3], S. Sofia[4], G. Pantò[4], C. Iacobello[4], M. Averna[2], B. Celesia[2], A. Marino[2], G. Nunnari[2], G. Madeddu[1]
[1]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [2]Infectious Diseases Unit, ARNAS Garibaldi Hospital, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, [3]School of Medicine, University of Sassari, Sassari, Italy, [4]Unit of Infectious Diseases, AOE "Cannizzaro", Catania, Italy

P 11 **Boosted Antiretroviral Regimens Are Strongly Associated with Clinically Significant Drug–Drug Interactions in People Living with HIV Aged ≥65 Years**
R. Ferri, T. Asciore, S.G. Rizzello, M. Pontolillo, K. Falasca, J. Vecchiet
Clinic of Infectious Diseases, SS. Annunziata Hospital - G. D'Annunzio University, Chieti- Pescara, Italy

P 12 **Cardiovascular prevention in people ageing with HIV: statin uptake in Lombardy, 2019-2025**
S. Villa[1,2], M. Maffeo[1,2], C. Tincati[3], V. Iannone[4,2], L. Rezzonico[5], L. Pezzati[6], F. Conti[7], E. Quiros-Roldan[8], C. Fornabaio[9], P. Vitiello[10], L. Pagnucco[11,2], A. Bandera[12], V. Spagnuolo[13], P. Bonfanti[14,15], M. Melazzini[1], G. del Castillo[1,2], D. Cereda[1,2]
[1]Directorate General for Health, Lombardy Region, Milan, Italy, [2]Regional Center for Infectious Diseases – CEREMI - Lombardy Region, Milan, Italy, [3]Infectious Disease Unit, ASST Santi Paolo e Carlo, Milan, Italy, [4]Infectious Disease Unit, ASST Fatebenefratelli Sacco, Milan, Italy, [5]Infectious Disease Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [6]Infectious Disease Unit, ASST Ovest Milanese, Legnano, Italy, [7]Infectious Disease Unit, ASST Lecco, Lecco, Italy, [8]Infectious Disease Unit, ASST Spedali Civili, Brescia, Italy, [9]Infectious Disease Unit, ASST Cremona, Cremona, Italy, [10]Infectious Disease Unit, ASST Valle Olona, Busto Arsizio, Italy, [11]Infectious Disease Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [12]Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [13]Infectious Disease Unit, Fondazione IRCCS San Raffaele, Milan, Italy, [14]Infectious Disease Unit, IRCCS San Gerardo dei Tintori, Monza, Italy, [15]University of Milano-Bicocca, Milan, Italy

P 13 **Dynamic of Blood Telomere Length in ART-Naive PWH over two Years after Starting ART**

F. Lombardi[1,2], M. Fabbiani[3], P.F. Salvo[1,2], G. Baldin[1], A. Carbone[1], S. Colaiuda[2], E. Visconti[1], E. Tamburrini[1,2], C. Torti[1,2], S. Di Giambenedetto[1,2]
[1]Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italia, Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, [2]Università Cattolica del Sacro Cuore, Roma, Italia, Dipartimento di Sicurezza e Bioetica sezione Malattie Infettive, [3]UOC Malattie Infettive e Tropicali, Azienda Ospedaliero-Universitaria Senese, Siena, Italy

P 14 **Estimates of HIV-diagnosed and HIV-undiagnosed using ECDC HIV-modelling tool, Italy 2010-2024**

M. Dorrucci, V. Regine, L. Pugliese, B. Suligoi
Department of Infectious Diseases, National Institute of Health, Rome, Italy

P 15 **From Survival to Meaning: Stigma, Multimorbidity and Intimacy as Core Dimensions of Aging with HIV in Italy**

G. Giupponi[1], A. Castro[2], S. Penon[3], M. Giannelli[4], A. Bianchi[5], S. Cecere[6], N. Policek[7], E. Marra[8], C. Buellis[9], G. Guaraldi[10]
[1]LILA Nazionale Como Italy, [2]University of Milan Bicocca Milan Italy, [3]LILA Milano Italy, [4]LILA Bari Italy, [5]ASA Milan Italy, [6]PLUS-rete Persone LGBT+ Bologna Italia, [7]NPS Italia Milano Italia, [8]Plus Roma Roma Italy, [9]CICA Milano Italy, [10]University of Modena e Reggio Emilia, Modena, Italy

P 16 **Negative impact of anticholinergic burden on depression, anxiety and quality of life in older people living with compared to HIV-negative controls: data from Italian multicentre GEPPO cohort**

B. Fioretti[1], S. Calza[2], S. Arsuffi[1], E. Goffi[3], A. Coin[4], C. Mussi[5], A. Riva[6], S. Piconi[7], S. Nozza[8], J. Milic[9], N. Squillace[10], G. Bellelli[11], G. Guaraldi[9], A. Calcagno[12], A. Marengoni[3], E. Focà[1]
[1]Division of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy, [2]Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, [3]Division of Geriatrics, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili of Brescia, Brescia, Italy, [4]Division of Geriatrics, Department of Medicine (DIMED), University of Padova, Padova, Italy, [5]Division of Geriatrics Medicine Dept of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena and Reggio Emilia, Italy, [6]3rd Division of Infectious Diseases, University of Milano, Ospedale L. Sacco, Milano, Italy, [7]Infectious Diseases Unit, Alessandro Manzoni Hospital, Lecco, Italy, [8]Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, [9]Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena e Reggio Emilia, Italy, [10]Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, [11]Acute Geriatric Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza and School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy, [12]Division of Infectious Diseases, Department of Translational medicine, UPO - Università del Piemonte Orientale, Novara, Italy

P 17 **Patients' and Physicians' Motivations for Considering Long Acting Cabotegravir and Rilpivirine in Older People with HIV**

A. Riva[1], J. Milic[2], B. Fioretti[3], C. Candela[4], F. Barrera[5], N. Gemignani[6], L. Curci[7], S. Gardini[8], N. Squillace[9], A. Franzò[10], A. De Vito[11], M.V. Cossu[1], S. Nozza[4], S. Piconi[6], G.V. De Socio[7], L. Sasset[8], P. Bonfanti[9], B.M. Celesia[10], G. Madeddu[11], S. Calza[12], E. Focà[3], G. Guaraldi[2], A. Calcagno[13]
[1]Department of Infectious Diseases, University of Milan, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, [2]Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy, [3]Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, [4]Infectious Disease Unit, Università Vita Salute San Raffaele, Milano, Italy, [5]Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, [6]Infectious Diseases Unit, Alessandro Manzoni Hospital, Lecco, Italy, [7]Infectious Diseases Clinic, Santa Maria Della Misericordia Hospital, Department of Medicine, University of Perugia, Perugia, Italy, [8]Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, [9]Infectious Diseases Unit, IRCCS Fondazione San Gerardo dei Tintori, Monza (MB), Italy, [10]Unit of Infectious Diseases, Department of Experimental and Clinical Medicine, ARNAS Garibaldi Hospital, University of Catania, Catania, Italy, [11]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [12]Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, [13]Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy

P 18 **The Hidden Workforce of HIV Aging: Caregiving, Stigma and System Fragmentation in the Italian Ministerial Healthy Aging Project**

A. Castro[2], C. Buellis[3], M. Belli[1], G. Giupponi[4], G. Guaraldi[1]
[1]University of Modena and Reggio Emilia, Modena, Italy, [2]University of Milan Bicocca, Milan, Italy, [3]CICA, Milan, Italy, [4]LILA Nazionale Como, Italy

P 19 **The pictorial fit-frailty scale and patient-reported outcomes in optimally-treated persons with HIV**

A. Barco[1], M. Sacchetti[2], O. Bargiacchi[1], F. Rinaldi[1], A.D. Frere[t2], M. Colafigli[3], F. Del Puente[4], A. Lanzardo[5], S. Tunesi[5], D. Vai[6], F. Barrera[6], L. Binaschi[2], A. Calcagno[1,7]
[1]SCDO Malattie Infettive, AOU Maggiore della Carità, Novara, Italy, [2]S.S.D Psicologia Clinica, AOU Maggiore della Carità, Novara, Italy, [3]Infectious Diseases Unit, U. Parini Hospital, Aosta, Italy, [4]Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, [5]Infectious Diseases Unit, AOU SS Antonio e Biagio e C. Arrigo, Alessandria, Italy, [6]Unit of Neurology, Maria Vittoria Hospital, Turin, Italy, [7]Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy

Antiretroviral Therapy

P 20 **B/F/TAF vs DTG: Similar durability, different reasons for discontinuation. Results of a real-life study**

V. Cogliandro[1], N. Squillace[1], E. Ricci[2], G. Orofino[3], L. Taramasso[4], B. Menzaghi[5], P. Maggi[6], S. Piconi[7], G.F. Pellicanò[8], E. Sarchi[9], G.V. De Socio[10], G. Madeddu[11], R. Gulminetti[12], E. Pontali[13], B.M. Celesia[14], T. Bini[15], E. Salomoni[16], G. Cenderello[17], S. Martini[18], A. Bandera[19], M. A. Carleo[20], S. Ferrara[21], A. Di Biagio[4], P. Bonfanti[1], for the CISAI Study Group

[1]Infectious Diseases Unit, Fondazione IRCCS San Gerardo Hospital-University of Milano-Bicocca, Monza, Italy [2]Fondazione ASIA Onlus, Buccinasco (MI), Italy, [3]Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, [4]Infectious Diseases Unit, Ospedale Policlinico San Martino – IRCCS per l'Oncologia; Department of Health's Sciences, University of Genoa, Genoa, Italy, [5]Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy, [6]Università degli Studi di Enna "Kore", Enna, Italy, [7]Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, [8]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, AOU Policlinico G. Martino, Messina, Italy, [9]Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, [10]Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy, [11]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy, [12]Fondazione IRCCS Policlinico S. Matteo, Infectious Diseases, University of Pavia, Pavia, Italy, [13]Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, [14]Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, [15]Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [16]Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy, [17]Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy, [18]Infectious Disease Unit, University Hospital Luigi Vanvitelli, Naples, Italy, [19]Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [20]Infectious Diseases and Gender Medicine Unit, Cotugno Hospital, AO dei Colli, Naples, Italy, [21]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy

P 21 **Breastfeeding in an Italian Woman Living with HIV with Sustained Viral Suppression: A Case Report**

M. Mazzoccoli, N. Alfieri, S. Dalzero, M. Ierardi, C. Paramithiotti, M. Terragnoli, L. Terracciano, E. Zaninetta, S. El Oksha, M.C. Lavorato, C. Tincati, G.C. Marchetti, T. Bini
ASST Santi Paolo e Carlo, Milan, Italy

P 22 **Causes of discontinuation of co-formulated DOR/TDF/3TC in art-experienced adults with HIV-: real-world data from a multicentric study in Florence, Italy**

G. Formica[1], C. Costa[2], G. Somma[1], C. Malcontenti[3], M. Pozzi[3], B. Borchi[3], C. Fiorelli[3], L. Attala[2], M. Pittorru[4], P. Corsi[3], G. Sterrantino[3], A. Bartoloni[1,3], F. Bartalesi[2], F. Lagi[3]
[1]Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, [2]Infectious Diseases Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Italy, [3]Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy, [4]Hospital Pharmacy, Careggi University Hospital, Florence, Italy

P 23 **Changing TAF/FTC/RPV to TAF/FTC/BIC: efficacy, tolerability, treatment satisfaction and convenience. Results from the Switch study**

G. Orofino[1], O. Bargiacchi[2], M. Guastavigna[1], A. Ianniello[3], G. Bo[4], F. Onelia[4], A. Montalbano[4], A. Barco[2], F. Rinaldi[2], G. Calleri[1]
[1]Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, [2]Infectious Diseases, A. O. Universitaria "Maggiore della Carità" di Novara, Novara, Italy, [3]Laboratory of Microbiology and Virology, Amedeo Di Savoia Hospital, ASL Città Di Torino, Turin, Italy, [4]Medical Science Department, University of Turin, Turin, Italy

P 24 **Clinical success and simplified management in pediatric HIV: transitioning from multi-drug liquid formulations to Single-Tablet Regimens (STR)**

M. Stracuzzi[1], F. Marinacci[1], C. Coppola[1], V. Giacomet[1,2]
[1]Pediatric Infectious Diseases, Luigi Sacco Hospital, ASST FBF SACCO, Milan, Italy, [2]Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università degli Studi di Milano, Italy

P 25 **Community-Based Peer-Led HIV Testing and Linkage to Care Among Adolescents in Southwest Cameroon: Implications for Reducing HIV-Related Morbidity**

T.E.A. Adeola[1], A. Fontu[2], L. Kana[3], N. Julienne[4], E.N. Cyril[5]
[1,2]Cameroon, Alliance for Community Initiative, Kumba, Cameroon, [3,4]Presse Jeune Development, Yaounde, [5]Cameroon, Cmmunity Center for Integrated Development, Muyuka, Cameroon

P 26 **Does Timing of ART Initiation Affect Immunovirological Outcomes in ISTI era? Preliminary data from a multicenter study in Apulia**

M. Poliseno[1], A. Cianciaruso[1], N. Colavito[1], A. Lugli[1], A. Narducci[2], A. Vergori[2], S. Lo Caputo[2], F. Di Gennaro[1], A. Saracino[1]
[1]Clinic of Infectious Diseases, Department of Regenerative and Precision Medicine and Jonian Area (DiMePre-J), University of Bari, Bari, Italy, [2]Infectious Diseases Unit, A.O.U. Policlinico Foggia, University of Foggia, Foggia, Italy

P 27 **Durability and reasons for discontinuation of Long-Acting Cabotegravir/Rilpivirine in Virologically Suppressed Adults with HIV: A Multicenter Real-World Experience in Tuscany (LAHIV)**

F. Lagi[1], S. Trevisan[2], M. Fabbiani[3], B. Rossetti[4], M. Piccica[5], A. Pampaloni[6], S. Modica[11], B. Menichini[7], S. Costarelli[8], C. Bianco[9], G. Sarteschi[10], M. De Gennaro[11], M. Turco[12], V. Donini[2], M. Maruotto[2], P. Corsi[1], M. Pozzi[1], M. Tumbarello[3], D. Messeri[7], C. Costa[5], B. Adriani[6], C. Nencioni[4], D. Tacconi[9], S. Sani[8], A. Vincenti[10], L. Pisano[12], F. Bartalesi[5], A. Bartoloni[1,2]
[1]SOD Malattie Infettive, Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze, Italy, [2]Dipartimento di medicina sperimentale e clinica, Università degli studi di Firenze, Italy, [3]Azienda Ospedaliero-Universitaria Siena, Università degli Studi di Siena, Italy, [4]UO Malattie Infettive, Ospedale di Grosseto, Azienda USL Toscana Sud Est, Italy, [5]SOC Malattie Infettive, Ospedale Santa Maria Annunziata, USL Toscana Centro, Italy, [6]UO Malattie Infettive, Azienda Ospedaliera Prato, USL Toscana Centro, Italy, [7]SOS Malattie Infettive, Azienda Ospedaliera Pistoia, USL Toscana Centro, Italy, [8]UO Malattie Infettive, Azienda Ospedaliera Livorno, USL Toscana Nord-Ovest, Italy, [9]UOC Malattie Infettive, Azienda Ospedaliera Arezzo, USL Toscana Sud-Est, Italy, [10]UO Malattie Infettive, Nuovo Ospedale Apuane, USL Toscana Nord-Ovest, Italy, [11]UO Malattie Infettive, Azienda Ospedaliera Lucca, USL Toscana Nord-Ovest, Italy, [12]S.C. Dermatologia, P.O. Piero Palagi, Usl Toscana Centro, Italy

P 28 **Early virological recovery in patients with extreme HIV viremia: Impact of treatment history and CDC clinical stage**
G. D'Agati[1,2], C. Conti[1,2], D. Marrali[1,2], S. Urso[1,2], M. Trizzino[1,2], L. Pipitò[1,2], A. Cascio[1,2]
[1]Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy, [2]Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy

P 29 **Extreme potency of Lenacapavir plus Long-Acting Cabotegravir and Rilpivirine in a heavily immunocompromised HTE patient: rapid virological suppression and the risk of IRIS**
A. Franzò[1], B. Bellocchi[1], A. Marino[1], V. Moscatt[1], M. Coco[1], V. Boscia[1], G. Vinci[1], M. Gussio[1], R. Caruso[2], G. Cannata[3], B.S. Cacopardo[1], G. Nunnari[1], B.M. Celesia[1]
[1]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, Catania, Italy, [2]Unit of Anaesthesia and Intensive Care Unit, ARNAS Garibaldi Nesima Hospital, Catania, Italy, [3]Unit of Anaesthesia and Critical Care Medicine III - CAST, Policlinico University Hospital, Catania, Italy

P 30 **Immunological Outcomes After Switch to Long-Acting Cabotegravir/Rilpivirine: A Real-World Monocentric Experience**
A. Gizzi, M. Abbott, F. Guida Marascia, S. Agrenzano, C. Imburgia, A. Sanfilippo, G. Pipitone, C. Iaria
Infectious Disease Unit - ARNAS Civico-Di Cristina-Benfratelli, Palermo, Italy

P 31 **Impact of neuropsychiatric adverse events after switch from bictegravir-including to doravirine-including triple antiretroviral regimen in clinical setting**
L. Serroni, M. Ferrara, M. Tettoni, L. Trentini, S. Bonora
Unit of Infectious Diseases, Departement of Medical Sciences, University of Torino, Torino, Italy

P 32 **Long-term renal outcomes after switch to bictegravir: determinants of clinically significant decline at week 144 in the BICTEL cohort**
L. Bortolani, R. Donà, A. Lazzaro, F. Alessi, M. Ridolfi, E. Altavilla, C. Carafa, S. Figliomeni, G. Ceccarelli, C.M. Mastroianni, G. d'Ettorre
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

P 33 **Longitudinal Immunological and Metabolic Outcomes in Treatment-Experienced Women Switching to B/F/TAF: A 24-Month Dual-Center Real-World Study**
V. Speciale[1], A. Gasperin[2], G. Mancarella[2], R. Marocco[2], D. Di Trento[2], L. Ansaldo[2], M. De Masi[2], A. Di Nardo[1], L. Mazzanti[1], L. Bresciani[1], S. Iaquinandi[1], S. Vita[4], V. Filippi[3], A. Carraro[3], C. Pasquazzi[3], C. Del Borgo[2], M. Lichtner[4]
[1]Sapienza, University of Rome, Italy, [2]Infectious Disease Department, Santa Maria Goretti Hospital, Latina, Italy, [3]Infectious Disease Department, Sant'Andrea Hospital, Rome, Italy, [4]Department of NESMOS, Sapienza, University of Rome, Italy

P 34 **Outcomes of doravirine-based regimens in virologically suppressed ART-experienced persons with HIV: data from the Icona Cohort**
A. d'Arminio Monforte[1], A. Tavelli[1,2], R. Gagliardini[3], L. Taramasso[4], N.B. Bana[5], N. Squillace[6], T. Bini[7], D. Segala[8], E. Quiros-Roldan[9], S. Lo Caputo[10], A. Saracino[11], A. Antinori[3] on behalf of the ICONA Foundation Study Group - ICONA cohort
[1]ICONA Foundation, Milan, Italy, [2]National PhD Programme in One Health approaches to infectious diseases and life science research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy, [3]Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, [4]Infectious Disease Clinic, IRCCS Ospedale Policlinico San Martino, Genova, Italy, [5]Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [6]Department of Infectious Diseases, IRCCS San Gerardo dei Tintori, Monza, Italy, [7]Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, Milan, Italy, [8]Infectious Diseases Unit, Department of Translational Medicine, University of Ferrara, Ferrara, Italy, [9]Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy, [10]Clinic of Infectious Diseases, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy, [11]Clinic of Infectious Diseases, Department of Precision and Regenerative Medicine and Ionian Area, Polyclinic of Bari, University Hospital Polyclinic, University of Bari, Bari, Italy

P 35 **Prescribing appropriateness and economic sustainability of antiretroviral therapy: impact of a multidisciplinary pharmacist–infectious disease specialist collaboration**
M. Degli Antoni[1], S. Enisci[2], L. Zanichelli[1], C. Colarossi[1], A. Ruggieri[1], M.C. Granelli[2], F. Trapani[1]
[1]Infectious Diseases Unit, AUSL Piacenza, Piacenza, Italy, [2]Hospital Pharmacy and Direct Drug Distribution Unit, AUSL Piacenza, Piacenza, Italy

P 36 **Real-World Durability, Safety and Changes in Lipid and Body Weight Profiles with B/F/TAF: A 24-Month Observational Study**
A. Gasperin[1], G. Mancarella[1], V. Speciale[2], R. Marocco[1], M. De Masi[1], D. Di Trento[1], L. Ansaldo[1], A. Di Nardo[2], L. Mazzanti[2], S. Vita[3], A. Carraro[3], M. D'Achille[4], V. Rossi[4], C. Del Borgo[1], M. Lichtner[5]
[1]Infectious Disease Department, Santa Maria Goretti Hospital, Latina, Italy, [2]Sapienza, University of Rome, Italy, [3]Infectious Disease Department, Sant'Andrea Hospital, Rome, Italy, [4]Nurse Unit, Infectious Disease Department, Santa Maria Goretti Hospital, Latina, Italy, [5]Department of NESMOS, Sapienza, University of Rome, Italy

P 37 **Retention in HIV Care and Loss to Follow-Up in a Single-Centre Cohort: A 10-Year Analysis**
A. Bilotta[1], A. De Vito[1], E. Ghisu[1], A. Colpani[2], A. De Filippi[3], G. Moi[1], G. Madeddu[1]
[1]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [2]Unit of Infectious Diseases, Department of Medicine, San Francesco Hospital ASL-3 Nuoro, Nuoro, Italy, [3]School of Medicine, University of Sassari, Sassari, Italy

P 38 **Switch from DRV/c/FTC/TAF to BIC/FTC/TAF in virologically suppressed people with HIV**
G. Massobrio[1], M. Muccio[2], G. Cologgi[1], G. Sbraccia[1], M. Nofri[2], S. Cardaci[2], M. Bassetti[1,2], L. Taramasso[2], A. Di Biagio[1,2]
[1]Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy, [2]Department of Specialist Medicine, Infectious Disease Clinic, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy

P 39 **Switch to a once-daily single-tablet regimen in children living with HIV with suboptimal adherence: virologic and immunologic outcomes**
V. Santoiemma, C. Cafagno, A. Orlandi, D. Tricarico, D. Caselli
Giovanni XXIII Pediatric Hospital, Bari, Italy

P 40 **The Interplay of Congenital HIV Infection and Renal Function: Assessing Long-term Outcomes in Pediatric and Adolescent Population**
S.G. De Maria, G. Lorenzetti, A. Cascone, C. Tripiciano, M. De Luca, L. Romani, L. Cursi, L. Colagrossi, R. Scutari, C.F. Perno, S. Bernardi
Bambino Gesù Pediatric Hospital, Rome, Italy

P 41 **Treatment of advanced naive HIV-infected patients with Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV advanced naive patients: data from a real-life cohort**
S. Martini[1], A. Russo[1], G. Ricciardiello[1], C. Cacace[1], F. La Guardia[1], L. Salmoni[1], A. Masielllo[2], V. Iodice[2], A. Del Villano[2], M. Pisaturo[1], C. Sagnelli[1,2], N. Coppola[1]
[1]UOC Malattie infettive Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, [2]AORN Sant'Anna e San Sebastiano di Caserta, Italy

P 42 **Treatment optimisation in antiretroviral-experienced subjects treated with darunavir 600mg BID including regimes**
D. Ripamonti[1], D. Valenti[2], A. Francavilla[2], L. Comi[1], S. Venturelli[1], N. Galizzi[1], F. Borghi[1], F. Zoboli[1], F. Crippa[1], M. Zazzi[3]
[1]ASST Papa Giovanni XXIII, Bergamo, Italy, [2]FROM - Fondazione per la Ricerca Ospedale di Bergamo - ETS, Bergamo, Italy, [3]Department of Medical Biotechnology, Virology Unit, University of Siena, Siena, Italy

P 43 **Trends in real-world antiretroviral therapy use in the Lombardy Region, 2023–2025**
A. Pedot[1,2], M. Maffeo[3,20], G. Del Castillo[1,20], N. Bana[4], T. Bini[5], A. Giacomelli[3,21,20], M. Mena[6], M. Cerri[7], S. Pagano[8], M. Bottanelli[9], E. Quiros-Roldan[10,11], C. Fornabaio[12], A. Vavassori[13], G. Mulè[14], L. Pagnucco[15,20], A. Bandera[16], P. Bonfanti[17], A. Castagna[18,19], M. Melazzini[1], D. Cereda[1,20]
[1]Directorate General for Health - Lombardy Region, Milan, Italy, [2]Department Biomedical Sciences for Health - University of Milan, Milan, Italy, [3]ASST Fatebenefratelli Sacco - University Hospital, Milan, Italy, [4]Department of Infectious Diseases - ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [5]Infectious diseases unit - ASST Santi Paolo e Carlo, Milan, Italy, [6]Infectious diseases unit - ASST Ovest Milanese, Legnano, Italy, [7]Infectious diseases unit – ASST Lodi, Lodi, Italy, [8]Infectious diseases unit - ASST Sette Laghi, Varese, Italy, [9]Infectious diseases unit - ASST Lecco, Lecco, Italy, [10]Infectious diseases unit – ASST Spedali Civili di Brescia, Brescia, Italy, [11]Brescia University, Brescia, Italy, [12]Infectious diseases unit – ASST Cremona, Cremona, Italy, [13]Infectious diseases unit – ASST Mantova, Mantova, Italy, [14]Infectious diseases unit - ASST della Valle Olona, Busto Arsizio, Italy, [15]Infectious diseases unit - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [16]Infectious diseases unit -Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico - University of Milan, Milan, Italy, [17]Infectious Diseases Unit- Fondazione IRCCS, San Gerardo dei Tintori - University of Milano-Bicocca, Monza, Italy, [18]Vita-Salute San Raffaele University, Milan, Italy, [19]IRCCS San Raffaele Scientific Institute, Milan, Italy, [20]Regional Center for Infectious Diseases – CEREMI - Lombardy Region, Milan, Italy, [21]Department of Biomedical and Clinical Sciences – University of Milan, Milan, Italy

P 44 **Undetectable at last: viral suppression after over 30 years in a person living with pan-resistant HIV following lenacapavir introduction**
D. Diana[1,2], T. Clemente[3], D. Canetti[3], C. Muccini[3], G. Annicchiarico[3], C. Ballabio[1], A. Castagna[1,3], V. Spagnuolo[1,3]
[1]Vita-Salute San Raffaele University, Milan, Italy, [2]University of Naples Federico II, Naples, Italy, [3]Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

P 45 **Validation of the 90% Proportion of Days Covered Threshold Against the WHO 95% Virological Success Target in People Living with HIV**
F.V. Segala[1], E. Vania[1], D. Mengato[2], D. Leoni[1], S. Gardin[1], A. Ferrari[1], G. Berti[2], L. Sasset[1], A. Cattelan[1,3]
[1]Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, [2]Hospital Pharmacy Unit, Azienda Ospedale-Università Padova, Padua, Italy, [3]Department of Molecular Medicine, University of Padua, Padua, Italy

P 46 **Viro-immunological effectiveness of DOR/3TC/TDF as a switch regimen after 144 weeks of observation in the DOROTEA study cohort**
A. Ciccullo[1], G. Baldin[2], A. Tommasi[3], A. Cervo[4], G. Formica[5], M.V. Cossu[6], M. Fabbiani[7], E. Altavilla[8], G. Madeddu[9], S. Colaiuda[10], F. Lagi[5], C. Papalini[3], A. Giacomelli[6], C. Mussini[4], S. Di Giambenedetto[2,10]
[1]Infectious Diseases Unit, Ospedale San Salvatore, L'Aquila, Italy, [2]Infectious Diseases Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, [3]Department of Medicine and Surgery, Section of Infectious Diseases, University of Perugia, Perugia, Italy, [4]Department of Infectious Diseases, Azienda Ospedaliero-Universitaria of Modena, Modena, Italy, [5]Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, [6]Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, [7]Department of Medical Sciences, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, [8]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [9]Infectious Diseases Unit, University of Sassari, Sassari, Italy, [10]Catholic University of the Sacred Heart, Rome, Italy

P 47 **Virological, immunological and metabolic outcomes after switch to Dual Therapy with Lamivudine + Doravirine in virologically suppressed People living with HIV (PLWH): a 24-Month real-world study**
F. Vignale, K. Luzi, L. Caiazzo, G. Vandi, C. Biagetti
Clinic of Infectious Diseases, Infermi Hospital, Rimini, Italy

Cancer

P 48 **Extracavitary Primary Effusion Lymphoma as an HHV-8–Driven Lymphoproliferative Disorder in Advanced HIV: A Case Series**
E. Matteini[1], M. Bibas[2], I. Mastrorosa[1], A. Mondi[1], C. Pinnetti[1], S. Grisetti[1], F. Baldini[1], D. Colombo[3], F. Del Nonno[3], V. Mazzotta[1], A. Antinori[1]
[1]HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, [2]Hematology Service, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy, [3]Pathology Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy

P 49 **Five-year cancer mortality among people with HIV: a monocentric retrospective study**
M. Matone[1], G. Pozza[1], D. Dalu[2], L. Oreni[1], C. Fasola[2], M.V. Cossu[1], G. Carrozzo[1], A. Poloni[1], C. Fusetti[1], D. Moschese[1], N. La Verde[2], A. Gori[1,3,4], A. Giacomelli[1,3]
[1]Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Milan, Italy, [2]Department of Oncology, ASST Fatebenefratelli Sacco, Luigi Sacco University Hospital, Milan, Italy, [3]Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, [4]Centre for Multidisciplinary Research in Health Science (MACH), Milan, Italy

P 50 **From guidelines to clinical practice: Lung Cancer Screening Adherence, preliminary data from the Modena HIV Cohort**
F. Calandra Buonaura[1], E. Delmonte[1], F. Prandini[1], U. Calvi[1], A. Cervo[2], G. Cuomo[2], M. Menozzi[2], C. Mussini[1]
[1]Infectious Diseases Clinic, University of Modena and Reggio Emilia, Modena, Italy, [2]Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria, Policlinico of Modena, Modena, Italy

P 51 **Uptake of anal cancer screening among transgender women with HIV**
S. Lazzarin[1], C. Fusetti[1], F. Caruso[1], A. Giacomelli[1,2], L. Oreni[1], M.V. Cossu[1], F. Petri[1], V. Iannone[1], C. Gervasoni[1], A.L. Ridolfo[1], A. Riva[1,2], A. Gori[1,2], D. Moschese[1]
[1]Department of Infectious Diseases, ASST Fatebenefratelli-Sacco University Hospital, Milan, Italy, [2]Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy

Epidemiology, Social Sciences and PROs

P 52 **2011-2025 Health and social care for PLWH in HIV/AIDS out-of-hospital facilities in Lombardy**
L. Rancilio, T. Bianchini, C. Castelli, M. Deghi, G. Gaiera, P. Meli
Coordinamento Case Alloggio per persone con HIV/AIDS della Lombardia (CRCA Lombardia) - CICA, Milano, Italy

P 53 **A decade of hepatitis C prevention in young people: a patient association-led educational model in school and community settings in southern Italy**
A. Cavallaro, M.C. Muscio, M. Bartoli, M. Conforti
Associazione Epac-ETS, Monza, Italy

P 54 **A Physician-Supervised, Nurse-Led Model for Long-Acting Antiretroviral Therapy: Patient-Reported Experience from a Dedicated Outpatient Service**
M.V. Cossu[1], M. Matone[1], D. Moschese[1], A. Bergna[1], A. Riva[1,2], A.L. Ridolfo[1], C. Gervasoni[1], A. Gori[1,2,3]
[1]Department of Infectious Diseases - ASST FBF Sacco, Milan, Italy, [2]DIBIC Luigi Sacco, University of Milan, Italy, [3]Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy

P 55 **Analysis of the Characteristics of PWH Followed at the Infectious Diseases Clinic of Udine: A Historical Cohort Study**
T. Semenzin[1], C. Tascini[1,2], S. Lanini[1,2]
[1]University of Udine Department of Medicine (DMED), Udine, Italy, [2]Infectious Diseases Clinic, Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Udine, Italy

P 56 **Between Control and Silence: Chemsex Practices, Disclosure, and Stigma in an Italian Regional Survey**
S. Mattioli, S. Cecere, S. Maugeri, M. Degli Esposti, P. Morabito, G. Spreafico, E. Richero
Plus aps - PrEP Point Plus, Bologna, Italy

P 57 **Beyond the Screen: identifying informational gaps and communicative patterns in STI prevention for students of some schools in the area of Rome**
A. Colucci, C. Gallo, M. Schwarz, R. Dalla Torre, E. Fanales Belasio, P. Gallo, A. D'Agostini, R. Valli
Unità Operativa Ricerca psico-socio-comportamentale, Comunicazione, Formazione, Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy

P 58 **Beyond viral suppression: biomedical reductionism, cultural competence, and psychosocial needs among GBQ men living with HIV in Italy**
E. Mura[1,2], F. Cocco[3], I. Massa[4], G. Dessi[1], D. Lasio[3]
[1]LILA Cagliari OdV, Cagliari, Italy, [2]Dipartimento di Scienze Politiche e Sociali, Università degli Studi di Cagliari, Cagliari, Italy, [3]Dipartimento di Pedagogia, Psicologia, Filosofia, Università degli Studi di Cagliari, Cagliari, Italy, [4]Centre for Social Studies, University of Coimbra, Portugal

P 59 **Breaking barriers to HIV testing: the role of LILA in reaching the untested people in Italy**
G. Dessi, G. Giupponi, P. Perone
LILA Lega Italiana per la Lotta contro l'AIDS, Como, Italy

P 60 **Care Pathways and Treatment Experience in Older People with HIV: Evidence from the Italian Healthy Aging Survey**
G. Guaraldi[1], A. Castro[2], C. Buellis[2], M. Belli[3], J. Milic[1], G. Giupponi[4]
[1]University of Modena and Reggio Emilia, Modena, Italy, [2]University of Milano Bicocca, Milan, Italy, [3]CICA, Milan, Italy, [4]LILA Milano, Milan, Italy

P 61 **Chemsex and the transformation of erotic fantasy: a survey study**
G. Fracca, M. Manfredini, A. Antonino, A. Bianchi, M. Cernuschi
ASA ODV Milano, Italy

P 62 **Clinical case: MDPV-related Chemsex addiction in a 25-year-old MSM — integrated multi-agency intervention**
G. Fracca
ASA ODV, Milano, Italy

P 63 **Community-based peer-support program integrated into a hospital-based testing service: a descriptive analysis of a pilot program**
G.V. Calvino[1], N. Braccialarghe[2], G. Scarfo'[1], V. Barchi[2], A. Giacinta[2], R. Esvan[2], G. Micheli[2], A. Antinori[2], V.L. Del Negro[1], V. Mazzotta[2]
[1]Checkpoint Plus Roma, Rome, Italy, [2]Istituto nazionale per le malattie infettive "L. Spallanzani" IRCCS Rome, Italy

P 64 **Comparison of HIV incidence between MSMs, Heterosexual Males and Females in Italy from 2012 to 2024**
L. Pugliese, V. Regine, B. Suligoi
Department of Infectious Diseases, National Institute of Health, Rome, Italy

P 65 **Democratizing U=U: addressing educational disparities in HIV literacy in Brescia**
M. Stizioli, A. Bergomi, C. Davini, A. Sala, G. Varia
Brescia Checkpoint ETS, Brescia, Italy

P 66 **Determinants of HIV and STI Testing Uptake: Findings from a Study Conducted by the Istituto Superiore di Sanità**
E. Fanales Belasio, P. Gallo, A. Colucci, R. Valli, M. Schwarz, R. Dalla Torre, C. Gallo, A. D'Agostini
Unità Operativa Ricerca psico-socio-comportamentale, Comunicazione, Formazione, Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy

P 67 **Four years of Ancona checkpoint: characteristics of tested population and outcomes of newly discovered HIV infections**
S. Caucci[1,2], L. Saracini[2,3], P. Pauri[2], A. Costantini[4], L. Butini[4,5]
[1]Microbiology Unit, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, [2]Ancona Checkpoint, Ancona, Italy, [3]Ass. Opere Caritative Francescane, Ancona, Italy, [4]Clinical Immunology Unit, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy, [5]Anlaids Marche APS, Italy

P 68 **Heteronormative clinical frameworks and STI risk assessment among women who have sex with women in Italy**
I. Massa[1], F. Cocco[2], E. Mura[3,4], D. Lasio[2]
[1]Centre for Social Studies, University of Coimbra, Portugal, [2]Dipartimento di Pedagogia, Psicologia, Filosofia, Università degli Studi di Cagliari, Cagliari, Italy, [3]Dipartimento di Scienze Politiche e Sociali, Università degli Studi di Cagliari, Cagliari, Italy, [4]LILA Cagliari OdV, Cagliari, Italy

P 69 **HIV-related stigma among healthcare workers in Italy: results from a Kwodledge Attitudes and Practices HIV survey**
S. Vita[1], A. Carraro[2], R. Marocco[3], L. Mazzanti[2], V. Speciale[2], L. Bresciani[2], V. Filippi[4], C. Pasquazzi[1], L. Germani[4], C. Del Borgo[3], M. Lichtner[1]
[1]Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome, Rome, Italy, [2]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [3]Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, [4]Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy, [4]Infectious Diseases Unit Sant'Andrea, Rome, Italy

P 70 **Improvement in patient-reported outcomes (PROs) after one year of long-acting Cabotegravir and Rilpivirine**
S. Rapino[1], S. Arsuffi[1], S. Calza[2], G. Tiecco[1], B. Fioretti[1], C. Anzoni[1], I. Polesini[1], F. Castelli[1], E. Quiros-Roldan[1], E. Focà[1]
[1]Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia e ASST Spedali Civili di Brescia, Italy, [2]Unità di Biostatistica e Biomatematica e Unità di Bioinformatica, Dipartimento di Medicina Molecolare e Traslazionale, Università degli Studi di Brescia, Italy

P 71 **Integrating Male and Female Condom Social Marketing to Strengthen Community-Based HIV Prevention in Kumba and Its Environs, Southwest Cameroon: Seven-Year Implementation Outcomes (2009–2016)**
A. Fontu[1], T.E. Adeola[1], E. Joseph[1], E.N. Cyril[2], L. Kana[3]
[1]Alliance for Community Initiative, Kumba, Cameroon, [2]Community Center for Integrated Development, Buea Cameroon, [3]PRESSE JEUNE DEVELOPPEMENT, Douala Cameroon

P 72 **LESSAIDS: Barriers to HIV Testing and Missed Healthcare Opportunities Before Diagnosis in Southern Italy**

A. Russo[1,2], S. Martini[2], G. Ricciardiello[2], M. Carleo[3], F.M. Fusco[4], N. De Gennaro[5], A. Gallicchio[6], A. Masiello[7], E. Zappulo[8], A. Auricchio[9], M. Trizzino[10], P. Fusco[11], A. Giaccone[12], V. Esposito[3], V. Sangiovanni[4], A. Saracino[5], E. Manzillo[6], C. Sagnelli[7], I. Gentile[13], A. Prozzo[9], A. Cascio[10], A. Russo[14], A. Franco[12], E.M. Trecarichi[1], N. Coppola[2]
[1]Link Capus University, Rome, Italy, [2]UOC Malattie Infettive, AOU Vanvitelli, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy, [3]UOC Malattie Infettive e Medicina di genere, PO Cotugno, AORN dei Colli, Naples, Italy, [4]UOC Malattie Infettive dell'immunodepresso, PO Cotugno, AORN dei Colli, Naples, Italy, [5]UOC Malattie Infettive, AOU Bari, Università degli Studi di Bari "Aldo Moro", Bari, Italy, [6]UOC Malattie Infettive e dell'immigrazione, PO Cotugno, AORN dei Colli, Naples, Italy, [7]UOC Malattie Infettive, AORN di Caserta, Caserta, Italy, [8]UOC Malattie Infettive, AOU Federico II, Università degli Studi di Napoli "Federico II", Naples, Italy, [9]UOC Malattie Infettive, AO Antonio Cardarelli di Campobasso, Campobasso, Italy, [10]UOC Malattie Infettive, AOU Palermo, Università degli Studi di Palermo, Palermo Italy, [11]UOC Malattie Infettive, AOU Renato Dulbecco, Catanzaro, Italy, [12]UOC Malattie Infettive dell'età geriatrica, VII Divisione, PO Cotugno, AORN dei Colli, Naples, Italy, [13]Università degli Studi di Napoli Federico II, Dipartimento di Medicina Clinica e Chirurgia, Naples, Italy, [14]UOC Malattie Infettive, AOU Catanzaro, Università degli Studi "Magna Grecia", Catanzaro, Italy

P 73 **Longitudinal ART adherence and clinical retention in women living with HIV: a 32-year retrospective study on the postpartum transition and long-term maternal outcomes**

D. Segala[1,2], G. Amaddeo[1], P. Mori[2], R. Cultrera[1,3]
[1]University of Ferrara, Ferrara, Italy, [2]Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy, [3]Azienda Unità Sanitaria Locale di Ferrara, Ferrara, Italy

P 74 **"Love Me While Playing School": a curriculum for learning about affectivity and sexuality in schools**

I. Ciciolla, A. Calluso, N. Catucci, M. Di Tullio, R. Giusto, M. Giannelli, G. Labianca, A. Degiosa, I.V. Lanera
C.A.M.A. – Centro Assistenza Malati Aids – OdV ETS, Bari, Italy

P 75 **Management of a Complex Chemsex Case: An Opportunity for Linkage to Care and Retention in Care**

A. Antonino[1], A. Bianchi[1], G. Fracca[1], D. Zagato[1], P. Testoni[1], P. Vinti[1], C. Soligo[1], M. Manfredini[1], S. Nozza[2], M. Cernuschi[1,2]
[1]ASA Onlus ODV, Milano, Italy, [2]San Raffaele Hospital, Milano, Italy

P 76 **Mapping school-based sexuality education interventions in Italian context, 2021-2025**

A. Cappagli, A. Chinelli, G. Paparatto, L. Tavoschi
Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy

P 77 **Mono-symptomatic therapeutical group for Chemsex users: 7 years of clinical experience in Milan**

G. Fracca, M. Manfredini, M. Cernuschi, A. Bianchi, A. Antonino
ASA ODV, Milano, Italy

P 78 **Neuropsychological disorders in women living with HIV: impact on quality of life**

E. Muresu[1], A. De Vito[1], G. Brugnani[2], M.E. Fajardo[1], G. Madeddu[1]
[1]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [2]School of Medicine, University of Sassari, Sassari, Italy

P 79 **Noi, Donne. From Perimenopause to Menopause. A Participatory Support Model for Women Living with HIV**

D. Russo[1], A. Moznich[1], A. Palmitesta[1], D. Peruzzi[1], S. Dalzero[2], L. Taramasso[3], N. Policek[1,4]
[1]NPS Italia Aps, Milan, Italy, [2]Department of Obstetrics and Gynaecology, DMSD San Paolo Hospital Medical School, University of Milan , Milan , Italy, [3]Infectious Diseases Unit, Policlinico San Martino Hospital - IRCCS, Genoa, Italy, [4]Executive Director, European AIDS Treatment Group (EATG), Brussels, Belgium

P 80 **Padova Checkpoint: the first year experience**

M. Falaguasta[1,2], G. Borgato[1,2], F. Sguotti[2], G. Giardina[1,2], F. Barbaro[1,3], A. Ferrari[1,3], D. Leoni[1,3], S. Cavinato[1,3], E. Vania[3], Calandrino[3], L. Sasset[1,3], A. Cattelan[1,3]
[1]Anlaids sez. Padova APS, Padova, Italy, [2]PadovaCheckPoint, Padova, Italy, [3]UOC Malattie Infettive e Tropicali AOPD, Padova, Italy

P 81 **Pathway for the Psychophysical Well-Being of People Living with HIV**

S. Negri[1], R. Galipò[2], P. Ferri[2], D. Mainieri[1], M. Massa[1], L. Butini[3]
[1]ANLAIDS Lombardia, Italy, [2]ANLAIDS Lazio, Italy, [3]ANLAIDS ETS

P 82 **Personality traits and health locus of control in people living with HIV: one year after long-acting therapy**

A. Romeo[1,3], M. Ferrara[2], V. Maccario[2], L. Trentini[2,3], M.C. Tettoni[2], S. Bonora[2]
[1]Department of Psychology, University of Turin, Turin, Italy, [2]Department of Medical Sciences, University of Turin, C/o Infectious diseases Unit, Amedeo di Savoia Hospital, Turin, Italy, [3]Anlaids sezione Torino ODV, Italy

P 83 **Reaching beyond key populations: five years of experience in community-based rapid HIV/STI testing**

N. Frattini[1], P. Vinti[1], E. Caruso[1], P. Russo[1,2], L. Nekrasova[1], R. Repossi[1], I. Gotti[1,3], D. Zagato[1,4], M. Cernuschi[1,4]
[1]Milano Check Point ETS, Milano, Italy, [2]CIG Arcigay Milano ODV, Milano, Italy, [3]ANLAIDS Sezione Lombarda ETS, Milano, Italy, [4]ASA ODV, Milano, Italy

P 84 **Suboptimal adherence and health concerns in people with HIV taking antiretroviral treatment in Italy: results from the Positive Perspectives 3 study**

D. Moschese[1], M.V. Cossu[1], M. Cascio[2], D. Gotti[3], E. Capoferro[3], T. Bendall[4], T.F. Hwang[5], C. Okoli[4], A. Appiah[4], N. Nwokolo[4], R. Patel[4]
[1]Department of Infectious Diseases, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, [2]European AIDS Treatment Group (EATG), Bruxelles, Belgium, [3]ViiV Healthcare, Verona, Italy, [4]ViiV Healthcare, London, UK, [5]ViiV Healthcare, Singapore, Singapore

P 85 **Temporary non-resident foreigner legal status is associated to late presentation among new HIV diagnoses in Milan, 2025**
G. Bozzi[1], M. Pernich[1,2], V. Castelli[1], A. Pastena[1], B. Mariani[1], A. Muscatello[1], A. Bandera[1,2]
[1]Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, [2]UNIMI - Università degli studi di Milano, Milano, Italy

P 86 **The Central Role of the Professional Educator in HIV Therapeutic Adherence**
G. Notore[1,2], I. Schenone[1,4], L. Ferrari[1,5], G. Manzi[1,2], A. Amoretti[1,2], F. Cucchetti[1,2], F. Tatta[1,4], F. Fadda[1,4], E. Pontali[1,5]
[1]ANLAIDS Sezione Liguria, Genoa, Italy, [2]University of Genoa, Genoa, Italy, [3]IRCCS AOM Ospedale Policlinico San Martino, Genoa, Italy, [4]Ente Ospedaliero Ospedali Galliera, Genoa, Italy

P 87 **The third sector in HIV care in Italy: mapping, value generation and sustainability challenges**
L. Brogonzoli[1], U. Restelli[2], M. Cascio[3,4], E. Sala[1], S. Silvola[2], A. d'Arminio Monforte[5], S. Nozza[3,6], N. Policek[3,7], S. Lo Caputo[3,8], S. Negri[3,9], R. Iardino[1]
[1]The Bridge Foundation, Milan, Italy, [2]LIUC Business School, Carlo Cattaneo University – LIUC, Castellanza, Italy, [3]HIV Outcomes Italy, Milan, Italy, [4]EATG (European AIDS Treatment Group), Brussels, Belgium, [5]Icona Foundation, Milan, Italy, [6]IRCCS-Ospedale S. Raffaele, Milan, Italy, [7]NPS Italia Onlus, Milan, Italy, [8]University of Foggia, A.O.U. Policlinico Foggia, Foggia, Italy, [9]ANLAIDS Lombardia ETS, Milan, Italy

P 88 **Three-Year Trends in Chemsex Among PrEP Clients and User-Identified Needs to Inform Integrated Risk-Reduction Services**
C. Fusetti[1], E. Caruso[2], S. Lazzarin[1], L. Nekrasova[2], F. Caruso[1], P. Vinti[2], V. Iannone[1], R. Repossi[2], A. Giacomelli[1,3], N. Frattini[2], M.V. Cossu[1], M. Cernuschi[2], A. Gori[1,3], D. Moschese[1,2]
[1]Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, [2]Milano Checkpoint ETS, Milan, Italy, [3]Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy

P 89 **Understanding the "Worried Well" phenomenon through Italy's AIDS and STIs Helpline**
M. Schwarz, P. Gallo, A. Colucci, E. Fanales Belasio, R. Valli, R. Dalla Torre, C. Gallo, A. D'Agostini
Unità Operativa Ricerca psico-socio-comportamentale, Comunicazione, Formazione - Dipartimento Malattie Infettive, Istituto Superiore di Sanità, Rome, Italy

P 90 **Villa Maraini Foundation-CRI: Boost access and quality of community-based communicable disease services in Italy. A pilot project**
P. Sammarco, D. Masci, G. Rodoquino, N. Gasbarrini, E. Rossi, M. Barra
Villa Maraini Foundation, Italian Red Cross, Rome, Italy

P 91 **When could it be too late? Factors associated with delayed HIV diagnosis: a retrospective study**
N. Bana[1], G. Cavazza[1,2], E. Di Gennaro[1,2], L. Luzi[1,2], A. Forni[1,2], F. Peracchi[1,2], L. Rezzonico[1], G. Burastero[1], C. Moioli[1], L. Chianura[1], G. Travi[1], R. Rossotti[1], M. Puoti[1,2]
[1]Department of Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [2]School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy

P 92 **When prevention meets stigma: multilevel stigma, mental health, and pre-exposure prophylaxis use among men who have sex with men. Findings from an online Italian survey via dating apps**
G. Cuomo, F. Calandra Buonaura, M. Menozzi, C. Mussini
University Hospital of Modena, University of Modena and Reggio Emilia, Italy

P 93 **"Would You do it more often?" A multimedia campaign and mobile outreach strategy to promote HIV/STI testing in Cagliari, Italy**
B. Mocci[1], A. Loddo[1], E. Mura[1,2], S. Campus[1]
[1]LILA Cagliari, Italy, [2]Dipartimento di Scienze Politiche e Sociali Università di Cagliari, Cagliari, Italy

Hepatitis/MASLD and other Liver Diseases

P 94 **Clinical outcomes after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) or entecavir (ETV) in chronic hepatitis B patients**
F. Cesanelli[1], O. Nozza[1], F. Gottardi[1], F. Mosti[1], G. Tiecco[1], S. Zaltron[2], A. Spinetti[2], F. Castelli[1], E. Quiros-Roldan[1,3]
[1]Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy, [2]Unit of Infectious and Tropical Diseases, ASST Spedali Civili di Brescia, Brescia, Italy, [3]Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden

P 95 **Diagnostic Invisibility of HBV: A 100% Dominant Multi-Mutant Escape Population (145R, 144E, 137W, 128V, 124R, 100C) Overcoming HBsAg Detection Layers**
B. Bruzzone[1], B. Galano[1], C. Fraccalvieri[1], S. Varesano[1], M. Mikulska[1,2], F. Benvenuto[1], N. Sessarego[1], G. Ubezio[1], F. Grillo[1,2], V. Ricucci[1]
[1]IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy, [2]University of Genoa, Genoa, Italy

P 96 **Evolution of HBV serological markers and reactivation risk in people living with HIV in the era of simplified antiretroviral therapy: a real-world experience**
D. Segala[1,2], T. Ferroni[1], R. Cultrera[1,3]
[1]University of Ferrara, Ferrara, Italy, [2]Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy, [3]Azienda Unità Sanitaria Locale di Ferrara, Ferrara, Italy

P 97 **Hepatic Health Restoration and Immune Optimization in ART-Naïve PWH Starting BIC/FTC/TAF: A 96-Week Multicenter Analysis of FIB-4 Dynamics and CD4/CD8 Ratio Abstract**

S. Spampinato[1,2,3], A. De Vito[4], D. Bivona[1], F. Velardita[1], A. Marino[1], B. Cacopardo[1], B.M. Celesia[1], G. Nunnari[1], G. Madeddu[4]
[1]Unit of Infectious Diseases, ARNAS "Garibaldi Nesima" Hospital, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, [2]Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy, [3]Unit of Infectious Diseases, "G. Martino" University Hospital, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, [4]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy

P 98 **Hepatitis delta screening cascade in people with HIV in a center in Milan**

A.R. Raccagni[1,2], R. Lolatto[1], H. Hasson[1], E. Messina[1], A. Siribelli[1], T. Clemente[1], M. Ripa[1,2], V. Spagnuolo[1,2], A. Danise[1], M. Guffanti[1], P. Cinque[1], D. Canetti[1], S. Nozza[1,2], A. Castagna[1,2]
[1]IRCCS San Raffaele Scientific Institute, Milan, Italy, [2]Vita-Salute San Raffaele University, Milan, Italy

P 99 **Immunological predictive factors for treatment response during bulevirtide therapy in HBV-HDV coinfected patients**

C. Taibi, E. Cimini, G. Grassi, A. Caioli, A. Rianda, F. Cristofanelli, S. Pauciullo, V. Zulian, A.R. Garbuglia, A.M. Geretti, E. Biliotti, G. D'Offizi
National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

P 100 **Invitation-based strategy and hepatitis C screening uptake in Tuscany, Italy**

S. Moriconi[1], E. De Vita[1], B.R. Porchia[2], D. Senatore[2], G. Bianco[2], R. Gusinu[3], S. Dei[3], P. Mantellini[3], P. Ferrante[1], S. Fondelli[1], L. Tavoschi[1]
[1]Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, [2]Directorate for Health, Welfare and Social Cohesion, Prevention, Health and Safety and Veterinary Sector, Regione Toscana, Florence, Italy, [3]Directorate of the Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy

P 101 **Metabolic-associated liver disease in people living with HIV: Preliminary results from a longitudinal observational study**

G. D'Agati[1,2], C. Gioè[1,2], C. Mazzola[1,2], C. Giordano[1,2], S. Urso[1,2], C. Conti[1,2], G. Valenti[1,2], M. Trizzino[1,2], L. Pipitò[1,2], A. Cascio[1,2]
[1]Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy, [2]Infectious and Tropical Disease Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy

P 102 **Opportunistic hospital screening for HCV elimination in the Autonomous Province of Trento: extension to the 1948–1989 cohorts**

M. Lanzafame[1,6], M. Gottardi[1], D. Fait[1], L. Guella[1], G. Stevanin[2], C. Pravadelli[3], L. Collini[4], D.A. Ramaroli[5]
[1]Unit of Infectious Diseases, Azienda Sanitaria Universitaria integrata trentina, Trento, Italy, [2]Provincial Hospital Service Management, Azienda Sanitaria Universitaria integrata trentina, Trento, Italy, [3]Unit of Gastroenterology, Azienda Sanitaria Universitaria integrata trentina, Trento, Italy, [4]Unit of Microbiology,Azienda Sanitaria Universitaria integrata trentina, Trento, Italy, [5]Department of Prevention, Azienda Sanitaria Universitaria integrata trentina, Trento,Italy, [6]University of Trento, Trento, Italy

P 103 **Persistent inflammatory signature during bulevirtide therapy in people with chronic hepatitis delta: analysis of IL-37 and IL-36 cytokines**

M. De Sanctis[1], S. Pauciullo[1], R. Sciamanna[1], E. Cimini[2], P. Del Porto[3], A.R. Garbuglia[1], V. Zulian[1]
[1]Laboratory of Virology, National Institute for Infectious Diseases "Lazzaro Spallanzani" (IRCCS), Rome, Italy, [2]Laboratory of Cellular Immunology and Pharmacology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [3]Department of Biology and Biotechnology "Charles Darwin", Sapienza University of Rome, Rome, Italy.

P 104 **Post-transplant comorbidities and MASLD development in liver recipients with and without HIV infection**

A. Cervo[1], M. Albertini[1], F. Casari[1], J. Milic[1,2], B. Catellani[4], P. Magistri[2,4], G. Guerrini[4], C. Mussini[1,2], G. Sebastiani[3], F. Di Benedetto[2,4], G. Guaraldi[1,2]
[1]Unit of Infectious Diseases, University Hospital of Modena, Modena, Italy, [2]Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio-Emilia, Modena, Italy, [3]Division of Gastroenterology and Hepatology, Chronic Viral Illness Service, McGill University Health Centre, Royal Victoria Hospital, Montreal, Canada, [4]Hepato-Pancreato-Biliary Surgery and Liver Transplantation Unit, University Hospital of Modena, Modena, Italy

P 105 **Results of real-world data from an outreach program for HCV diagnosis and treatment among key populations in Bologna**

J.M. Faiella Marsengo, A. Zuppiroli, L. Badia, P. Viale
Infectious Diseases Unit, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy

P 106 **Retrospective Evaluation of Lamivudine Prophylaxis for Prevention of Hepatitis B Virus Reactivation in Hematologic Patients Undergoing Chemotherapy (REPLAY): A Single-Center Experience**

S. Resuli[1], V. Severgnini[1], L. Maiocchi[1], P. Sacchi[1], G. Favrin[2], S. Pedrali[2], Y. Yudin[2], V.V. Ferretti[3], S. Rattotti[4], M. Gotti[4], E. Cappello[4], A. Parisotto[4], C. Cavalloni[4], A. Mazzacane[4], N. Polverelli[4], P. Zappasodi[4], S. Mangiacavalli[4], D. Ghirardi[2], L. Arcaini[2,4], R. Bruno[1,5], M. Varettoni[4], V. Zuccaro[1,5]
[1]Department of Infectious Diseases, IRCSS Policlinico San Matteo Foundation, Pavia, Italy, [2]Department of Molecular Medicine, University of Pavia, Italy, [3]Biostatistics and Clinical Trial Center, IRCCS Policlinico San Matteo, Pavia, Italy, [4]SC Ematologia 1, IRCCS Policlinico San Matteo, Pavia, Italy, [5]Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Italy

P 107 **Risk-Stratified HCC Surveillance in HIV–HBV/HCV Co-infection: Gaps Between Recommendations and Clinical Practice**

S. Generoso, E. Carriero, V. Bagnoli, M. Menozzi, G. Cuomo, G. Guaraldi, A. Cervo, C. Mussini
Infectious Diseases Clinic, University Hospital Policlinico of Modena, Modena, Italy

HIV and CNS

P 108 **A MUltidimensional Scale for Health needs in People with HIV: the prospective MUSA study**
A. Calcagno[1,2], E. Sala[3], M. Poliseno[4], M. Mazzitelli[5], G. Madeddu[6], B.M. Celesia[7], G. Marchetti[8], L. Petroli[1], M.V. Cossu[9], P. Cinque[10], S. Di Giambenedetto[11], M. Giacomini[12], R. Iardino[3], D. Vai[13], L. Brogonzoli[3], for the MUSA Research Group
[1]Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy, [2]Department of Translational Medicine, University of "Piemonte Orientale", Novara, Italy, [3]Fondazione The Bridge, Milan, Italy, [4]Clinic of Infectious Diseases, DiMePre-J, Università of Bari, Bari, Italy, [5]Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, [6]Unit of Immune Deficiency, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [7]Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, [8]Department of Health Sciences, Clinic of Infectious Diseases, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, [9]Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, [10]Unit of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, [11]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, [12]Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, Genoa, Italy, [13]Unit of Psychology, "Psicologia Aziendale", ASL "Città di Torino", Turin, Italy
The MUSA Research Group is composed by the authors and: A. Saracino | Clinic of Infectious Diseases, DiMePre-J, Università of Bari, Bari, Italy, A. Cattelan | Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, A. Gori | Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy, C. Torti | Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, L. Barbisoni | Infectious and Tropical Diseases Unit, Padua University Hospital, Padua, Italy, M. Strano| Unit of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy

P 109 **High-Resolution Insights into HIV-1 CNS Reservoirs: Clinical Utility of NGS-Based GRT in CSF with Variable Minority Variant Thresholds**
A. Parodi[1], F. Stefanelli[2], N. Randazzo[2], V. Ricucci[2], B. Bruzzone[2], M. Giurco[1], L. Costacurta[1], C.A. Bustamante[1], T.E. Ortiz Yupa[1], M. Bassetti[1,3], L. Taramasso[3], A. Di Biagio[1,3]
[1]Department of Health Sciences, University of Genoa, Genoa, Italy, [2]IRCCS Azienda Ospedaliera Metropolitana San Martino Hospital, Genoa, Italy, [3]Infectious Diseases Unit, IRCCS Azienda Ospedaliera Metropolitana San Martino Hospital, Genoa, Italy

P 110 **Neurosymptomatic CSF HIV escape in a woman on dual therapy**
M. Munarini, A. Zuppiroli, R.D. Barison, F. Baggio, S. Babini, L. Calza, G. Fasulo, P. Viale
Infectious Diseases Unit, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy

P 111 **Neurosyphilis and Ocular Syphilis: Clinical Spectrum, Laboratory Profile and Outcome in a 15-Year Retrospective Cohort at IRCCS San Raffaele Scientific Institute**
C. Candela[1], N. Capra[1], R. Lolatto[1], C. Tassan Din[1], M. Ranzenigo[1], S. Del Fabbro[2], G. Catalano[3], P. Cinque[1,3], A. Castagna[1,3], S. Nozza[1,3], E. Miserocchi[2,3]
[1]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, [2]Ophthalmology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, [3]Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy

P 112 **Stigma as a barrier to ART adherence: a case of advanced cerebral toxoplasmosis following treatment interruption**
V. Bleve[1], L. Bortolani[1], A. Falletta[1], A. Impellizzeri[1], L. Moretti[1], S. Rubino[1], E. Casali[2], M.R. Cuomo[2], C. D'Agostino[2], V. Mauro[2], G. Siccardi[2], C.M. Mastroianni[1], G. d'Ettorre[1]
[1]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy, [2]Infectious Diseases Unit, Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome, Italy

P 113 **Successful use of Fosmanogepix in relapsing cryptococcal meningitis in a PWH**
V. Brogna[1,2], N.B. Bana[2], A. Forni[1,2], L. Luzi[1,2], F. Peracchi[1,2], A. Repishti[1,2], M. Chiamenti[2], G. Travi[2], M. Vecchi[2], M. Puoti[2], P. Bonfanti[1], R. Rossotti[2]
[1]University of Milano-Bicocca, Milan, Italy, [2]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

P 114 **When mood meets cognition: updating mental and cognitive health of PLWH in the context of HAND**
G. Del Duca, A. Lener, G. Frate, M. Maresca, V. Mazzotta, R. Gagliardini, I. Mastrorosa, A. Antinori, C. Pinnetti
National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

Immunocompromised host: Infections and Therapy

P 115 **Cryptococcal antigenemia and multiple drug hypersensitivity in a "late presenter": a management challenge**
L. Abbate, T. Tibidò, A. Zuppiroli, S. Tedeschi, M. Munarini, L. Calza, P. Viale
Infectious Diseases Unit, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy

P 116 **HHV-8-associated multicentric plasmacytic Castelman disease in a treatment-naïve patient with LLV**
A. Del Villano[1], A. Masiello[2], V. Iodice[2], A.G. Iodice[2], A. Salzillo[2], F. Simeone[2], F. Colucci[2], G. Di Caprio[2], F.P. Fabozzi[1], R. Marmo[1], G. Falzarano[1], A. Corrente[1], G.M.Bottino[1], C. Sagnelli[1,2]
[1]Department of Mental, Physical, and Preventive Health, Infectious Diseases Section, University of Campania "Luigi Vanvitelli", Naples, Italy, [2]University-Directed Infectious and Tropical Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy

P 117 **Immuno-modulation of innate and adaptive immune response in patients with sepsis**
M. Antonacci[1], M.A. Zingaropoli[1], P. Pasculli[1], F. Dominelli[1], G. Galardo[2], E. Petrillo[2], R. Renna[2], G. Imbimbo[2], C.M. Mastroianni[1], M.R. Ciardi[1]
[1]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [2]Medical Emergency Unit, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy

P 118 **Impact of anti-CD20 therapy on T-follicular helper and CXCR5+ CD8+ T-cell subsets in multiple sclerosis: a preliminary longitudinal study**
F. Dominelli[1], M.A. Zingaropoli[1,2], P. Pasculli[1], M. Antonacci[1], F. Ciccone[1], M. Proietti[1], M. Lichtner[3], G. Ferrazzano[4], C.M. Mastroianni[1], A. Conte[4], M.R. Ciardi[1]
[1]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [2]Microbiology and Virology Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, [3]Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome, Rome, Italy, [4]Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy

P 119 **ITB screening and treatment in iatrogenically immune-depressed patients: a monocentric retrospective experience (2021-2024)**
M. Ticozzelli[1,2], L. Pezzati[2], F. Bassani[2], G. Canavesi[2], M. Rigoni[1,2], M.P. Bissanti[1,2], A.M. Tshishimbi[1,2], D. Bernacchia[2], S. Rusconi[1,2], G. Pagani[2]
[1]Università degli Studi di Milano, Milano, Italy, [2]SC Malattie Infettive, ASST Ovest Milanese, Ospedale di Legnano, Legnano, Italy

P 120 **Maribavir beyond refractory/resistant CMV infection: a monocentric experience**
L. Loiacono, I. Abbate, E. Cimini, R. Lionetti, E. Biliotti, F. Iacomi, F. Maggi, G.P. D'Offizi
INMI L. Spallanzani, Rome, Italy

P 121 **Pneumocystis jirovecii pneumonia in the ART era: differences between HIV and non-HIV immunocompromised patients in a referral center**
S. De Giorgi[1], G.M. Leanza[1], B. Allegretti[1], L. Lucarelli[1], M. Chiuchiarelli[2], F. Frondizi[2], R. Torelli[3], B. Fiori[3], A. Sanfilippo[4], A. Cingolani[1,2], C. Torti[1,2]
[1]Dipartimento di Sicurezza e Bioetica-Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy, [2]UOC Malattie Infettive-Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A.Gemelli IRCCS, Roma, Italy, [3]Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, [4]Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Roma, Italy

P 122 **Retroviruses 2.0: unmasking HIV-1/HTLV-1 coinfection in a woman with AIDS-defining conditions and elevated CD4+ counts. Insights from Brazil**
G. Catalano[1], J. Souza Silva[2], L. Batista[3], F. Carmo[3], A. Castagna[1,4], P. Cinque[4], J.E. Vidal[2,5]
[1]Vita-Salute San Raffaele University, Milan, Italy, [2]Neurology Service, Emílio Ribas Institute of Infectology, São Paulo, Brazil, [3]Emílio Ribas Institute of Infectology, São Paulo, Brazil, [4]IRCCS San Raffaele Scientific Institute, Milan, Italy, [5]Hospital das Clínicas, Faculty of Medicine, University of São Paulo, São Paulo, Brazil

Immunology and Inflammation

P 123 **Can routine hemocytometric indices be used as proxies for immune activation markers in people living with HIV?**
S. Vita[1], M. Guardiani[2], A. Carraro[2], A. Gasperin[3], M.A. Zingaropoli[2], L. Ansaldo[3], G. Mancarella[3], F. Dominelli[2], F. Mengoni[2], C.M. Mastroianni[2], R. Marocco[3], C. Del Borgo[3], M. Lichtner[1]
[1]Department of Neurosciences, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome, Rome, Italy, [2]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [3]Infectious Diseases Unit, SM Goretti Hospital, Sapienza University of Rome, Latina, Italy, [4]Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

P 124 **Different clinical and viro-immunological evolution of HIV-1 infection in two Long-Term Non-Progressor patients who shared the same virus**
L. Salmoni[1], S. Martini[1], A. Russo[1,2], N. Cuomo[3], A. Raddi[3], M. Starace[1], C. Minichini[1], M. Pisaturo[1], N. Coppola[1]
[1]Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, [2]Department of Life Science, Health, and Health Professions Link Campus University, Rome, Italy, [3]UOC Microbiologia e Virologia, Azienda Ospedaliera Speciaistica dei Colli Monaldi-Cotugno-C.T.O., Napoli, Italy

P 125 **Downregulation of CD8+CD38+DR+ Expression on T Cell After 10-year of Persistent and Fully Suppressive HIV therapy**
D. Ripamonti[1], L. Castellani[2], L. Comi[1], S. Venturelli[1], G. Cavazza[3], N. Galizzi[1], D. Valenti[4], F. Zoboli[1], A. Pagani[5], F. Crippa[1], A. Francavilla[4]
[1]Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, [2]Immunohematology and Transfusion Medicine. Department of Transfusion Medicine and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy, [3]School of Medicine and Surgery, University of Milan, Milan, Italy, [4]Bergamo Hospital Research Foundation – ETS (FROM), Bergamo, Italy, [5]Servizio Farmacia, ASST Papa Giovanni XXIII, Bergamo, Italy

P 126 **Extracellular Vesicles from Activated Vδ2 T Cells Inhibit Viral Replication and Enhance Adaptive Antiviral Immunity in immunocompromised hosts**
V. Bordoni[1], F. Guarracino[1], F. Marocco[2], L. Quattrocchi[2], A. Lorusso[1], A. Minutolo[3], S. Garbo[2], C. Matteucci[3], D. Pagliara[1], F. Galaverna[1], C. Battistelli[1], P. Merli[1], F. Locatelli[1], C. Agrati[1]
[1]Bambino Gesù Children's Hospital, IRCCS, Rome, Italy, [2]Sapienza University of Rome, Rome, Italy, [3]University of Rome Tor Vergata, Rome, Italy

P 127 **IL-6 as a potentially useful marker in the management of people living with HIV: links to immune activation and inflammation**
A. Gallicchio[1], A. Bianchi[1], A.M. Carleo[2], F.M. Fusco[3], A. Guida[2], A. Marocco[1], V. Rizzo[2], M. Sardo[1], E. Manzillo[1]
[1]UOC Malattie infettive dell'immunodepresso dell'immigrazione, [2]UOC Malattie infettive dell'immunodepresso e medicina di genere, [3]UOC Malattie infettive dell'immunocompromesso, Ospedali dei Colli Cotugno, Napoli, Italy

P 128 **Impact of STING1 variants on immune recovery and metabolic burden in older people living with HIV on long-term antiretroviral therapy**

I. Zanella[1,2], C. Fornari[3], F. Cesanelli[1,2], G. Tiecco[1,2], E. Zacchi[1,2,4], C. Bouros[1,2,4], S. Codenotti[1], R.M. Ferraro[5], A. Franzani[1], S. Giliani[1,5,6], E. Quiros-Roldan[1,2,7]
[1]Università degli Studi di Brescia, Brescia, Italy, [2]ASST Spedali Civili di Brescia, Brescia, Italy, [3]CIMeC, University of Trento, Rovereto, Italy, [4]University of Bologna, Bologna, Italy, [5]Angelo Nocivelli Institute for Molecular Medicine, Università degli Studi di Brescia, Brescia, Italy, [6]National Center for Gene Therapy and Drugs Based on RNA Technology-CN3, Brescia, Italy, [7]Karolinska Institutet, Stockholm, Sweden

P 129 **Virological, Immunological, and Metabolic Characteristics of Women Living with HIV: The CD4/CD8 Ratio as a Multidimensional Biomarker of Health**

S. Spampinato[1,2,3], G. Scuderi[4], E. Castro[1,2], M. Di Rosa[5], A. Marino[1,2], E. Venanzi Rullo[3], M. Paternò Raddusa[1], R. Bruno[1], N. Villari[1], G. Bruno[1], A. De Vito[6], G. Madeddu[6], B. Cacopardo[1,2], B.M. Celesia[1], P. Fagone[4], G. Nunnari[1,2]
[1]ARNAS Garibaldi Hospital, Unit of Infectious Diseases, Catania, Italy, [2]University of Catania, Department of Clinical and Experimental Medicine, Catania, Italy, [3]University of Messina, Department of Clinical and Experimental Medicine, Messina, Italy, [4]Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy, [5]Department of Biomedical and Biotechnological Sciences, Human Anatomy and Histology Section, School of Medicine, University of Catania, Catania, Italy, [6]Infectious Diseases Unit, University of Sassari, Sassari, Italy

Long Acting and new therapeutic scenarios

P 130 **96-Week Metabolic and Immunological Outcomes of Long-Acting Cabotegravir/Rilpivirine in Tuscany: Real-World Data from LAHIV**

F. Lagi[1], M. Maruotto[2], M. Piccica[3], G. Sarteschi[4], A. Pampaloni[5], B. Menichini[6], B. Rossetti[7], M. Sambo[8], S. Costarelli[9], C. Bianco[10], M. De Gennaro[11], S. Modica[11], P. Corsi[1], M. Pozzi[1], M. Turco[12], M. Tumbarello[8], S. Trevisan[2], C. Costa[3], B. Adriani[5], C. Nencioni[7], D. Messeri[6], D. Tacconi[10], S. Sani[9], A. Vincenti[4], L. Pisano[12], F. Bartalesi[3], A. Bartoloni[1,2]
[1]SOD Malattie Infettive, Azienda Ospedaliero-Universitaria Careggi, Università degli Studi di Firenze, Italy, [2]Dipartimento di medicina sperimentale e clinica, Università degli Studi di Firenze, Italy, [3]SOC Malattie Infettive, Ospedale Santa Maria Annunziata, USL Toscana Centro, Italy, [4]UO Malattie Infettive, Nuovo Ospedale Apuane, USL Toscana Nord-Ovest, Italy, [5]UO Malattie Infettive, Azienda Ospedaliera Prato, USL Toscana Centro, Italy, [6]SOS Malattie Infettive, Azienda Ospedaliera Pistoia, USL Toscana Centro, Italy, [7]UO Malattie Infettive, Azienda Ospedaliera Grosseto, USL Toscana Sud-Est, Italy, [8]Azienda Ospedaliero-Universitaria Siena, Università degli Studi di Siena, Italy, [9]UO Malattie Infettive, Azienda Ospedaliera Livorno, USL Toscana Nord-Ovest, Italy, [10]UOC Malattie Infettive, Azienda Ospedaliera Arezzo, USL Toscana Sud-Est, Italy, [11]UO Malattie Infettive, Azienda Ospedaliera Lucca, USL Toscana Nord-Ovest, Italy, [12]Section of Dermatology, Health Sciences Department, University of Florence, Florence, Italy

P 131 **Back to oral: immunovirological stability after Long-Acting CAB/RPV Interruption**

C. Grillo, A. Narducci, F.R.P. Ieva, S. Ferrara, I.F. Bottalico, A. Vergori, S. Lo Caputo
Infectious Diseases Unit, A.O.U. Policlinico Foggia, University of Foggia, Foggia, Italy

P 132 **Cardiometabolic Outcomes and Body Composition in PWH Switching to LA-CAB/RPV vs. Oral 2DR regimens**

F. Calandra Buonaura[1], J. Milic[1], S. Generoso[1], E. Delmonte[1], U. Calvi[1], F. Buffagni[1], M. Menozzi[2], G. Cuomo[2], G. Mancini[2], M. Menozzi[2], C. Mussini[1], G. Guaraldi[1]
[1]Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy, [2]Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy

P 133 **Durability in Real Life: Therapeutic Persistence and Injection Adherence with Long-Acting Cabotegravir/Rilpivirine**

C. Conti[1], M. Trizzino[1,2], C. Gioé[1,2], G. D'agati[1], S. Urso[1], A. Cascio[1,2]
[1]Università degli Studi di Palermo, Italy, [2]Unità di Malattie Infettive e Tropicali, AOU Policlinico "P. Giaccone", Palermo, Italy

P 134 **Escalating to "Target Not Detected": A Longitudinal Analysis of Enhanced Virologic Depth, Renal Dynamics, and Immunological Recovery in PWH Switching to CAB/RPV**

S. Spampinato[1,2,3], A. De Vito[4], D. Bivona[1], G. Migliazzo[1], A. Marino[1], R. Fontana del Vecchio[5], A. Franco[5], A. Montineri[6], C. Fasca[6], S. Sofia[7], G. Pantò[7], C. Cali[8], R. Bruno[1], N. Villari[1], C. Iacobello[6], B. Cacopardo[1], B.M. Celesia[1], A. Albanese[9], G.F. Pellicanò[3], E. Venanzi Rullo[3], G. Madeddu[4], G. Nunnari[1]
[1]Unit of Infectious Diseases, ARNAS "Garibaldi Nesima" Hospital, Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, [2]Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy, [3]Unit of Infectious Diseases, "G. Martino" University Hospital, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, [4]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy, [5]Unit of Infectious Diseases, Umberto I Hospital, ASP, Siracusa, Italy, [6]Unit of Infectious Diseases, "G. Rodolico-S. Marco" University Hospital, University of Catania, Catania,Italy, [7]Unit of Infectious Diseases, AOE "Cannizzaro", Catania, Italy, [8]Unit of Infectious Diseases, ASP Ragusa, Ragusa, Italy, [9]Unit of Infectious Diseases, "Papardo" Hospital, Messina, Italy

P 135 **HBV Replicative Activity by highly-sensitive droplet-digital-PCR in PWH Switching to CAB/RPV-LA therapy: preliminary results from the OBILART STUDY**

A. Magnapera[1], G. Piromalli[2] , I. Grossi[1], M. Ranzenigo[2], E. Messina[2], S. D'Anna[1], R. Lolatto[2], T. Clemente[2], L. Piermatteo[1], S. Bagaglio[2], R. Salpini[1], M.A. Pisaturo[4] ,V. Svicher[1], H. Hasson[2,3], A. Castagna[2,3]
[1]University of Rome Tor Vergata, Department of Biology, Rome, Italy, [2]Unit of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy, [3]Vita-Salute San Raffaele University, Milan, Italy, [4]Department of Mental and Physical Health and Medicine prevention, University of Campania L. Vanvitelli Naples, Italy

P 136 **Is isolated HBcAb a contraindication to switching to long-acting cabotegravir/rilpivirine?**

L. Pagnucco[1], R. Bruno[1,2], R. Gulminetti[1]
[1]Infectious Diseases Unit. Medical Department, Fondazione IRCCS Policlinico San Matteo University of Pavia, Pavia, Italy, [2]Department of Medicine, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy

P 137 **Long-acting Antiretroviral Therapy in Fragile PWH Followed in the Home Care Assistance: Real-life Experience in a Highly Clinically Complex Cohort**
C. De Vivo[1], S. Colaiuda[1], G. Lenzi[1], F.Lombardi[1,2], G. Cucinotta[1], F. La Fata[1], A. Carbone[1], L.Spina[1], P.F. Salvo[1,2], G. Baldin[1,2], C. Torti[1,2], S. Di Giambenedetto[1,2]
[1]Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, [2]Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy

P 138 **Management of acute HBV infection during long-acting antiretroviral therapy: a clinical case of successful oral bridge therapy and resumption after HBsAg seroconversion**
C. Parrotta, A. Zuppiroli, M. Giglia, L. Calza, P. Viale

Infectious Diseases Unit, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy

P 139 **Outcomes of dual Antiretroviral Therapy (ART) regimens in anti-HBc carriers: a comparative analysis**
A. Zuppiroli, M. Giglia, J.M. Faiella Marsengo, M. Munarini, L. Calza, P. Viale
Infectious Diseases Unit, IRCCS S. Orsola Hospital, University of Bologna, Bologna, Italy

P 140 **Real-world effectiveness and treatment persistence of long-acting cabotegravir/rilpivirine in women living with HIV**
L. Pagnucco[1], M.V. Cossu[2], M. Matone[2], C. Mariani[2], R. Solidoro[2], M.A. Muslimani[1], A. Riva [2,3], R. Gulminetti[1]
[1]Infectious Diseases Unit, Medical Department, Fondazione IRCCS Policlinico San Matteo University of Pavia, Pavia, Italy, [2]Department of Infectious Diseases - ASST FBF SACCO, Milan, Italy, [3]DIBIC Luigi Sacco, University of Milan, Italy

P 141 **Real-world eligibility and uptake of long-acting cabotegravir/rilpivirine in a structured screening program**
L. De Martino, A. Lazzaro, L. Maddaloni, C. Falvino, R.C. Carafa, L. Santinelli, C. M. Mastroianni, G. d'Ettorre
Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy

P 142 **Real-World Long-Term Outcomes of Cabotegravir/Rilpivirine Q8W With Extended Follow-Up**
M.V. Cossu[1], D. Moschese[1], M. Matone[1], A. Giacomelli[1,2], P. Olimpia[1], A. Riva[1,2], A.L. Ridolfo[1], C. Gervasoni[1], A. Gori[1,2,3]
[1]Department of Infectious Diseases - ASST FBF SACCO; Milan, Italy, [2]DIBIC Luigi Sacco, University of Milan; Milan, Italy, [3]Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy

P 143 **Switching to long-acting cabotegravir/rilpivirine versus maintaining oral therapy in virologically suppressed people with HIV: a multicentre, real-life comparison**
A. Palomba[1,2], M. Maccarrone[2], P.F. Salvo[3,4], A. Borghetti[1,2], A. Carbone[4], M. Polidori[1,2], G. Baldin[3], R. Cinelli[1,2], M. Falcone[1,2], S. Di Giambenedetto[3,4]
[1]Infectious Diseases Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, [2]Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, [3]Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy, [4]Dipartimento di Sicurezza e Bioetica, Sezione Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy

P 144 **Switching to Long-Acting Regimens in People with HIV: Real-World Experience and Analysis of the 2023 -2025 Period in an Italian Hospital**
M. D'Auria[1], N. Papa[2], V. Mattera Iacono[2], T. Di Caprio[2], M. Spatarella[2]
[1]Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy, [2]AORN - Ospedali dei Colli, Naples, Italy

P 145 **The role of resistance testing of HIV-DNA in PBMC when switching to Long Acting (LA) therapy: what guides clinical decision?**
S. Lerta[1,2], L. Pagnucco[2], G. Sangaletti[1,2], V.A. Villano[1,2], R. Gulminetti[2]
[1]University of Pavia, Department of Clinical-Surgical, Diagnostic, and Pediatric Sciences, Pavia, Italy, [2]Fondazione IRCCS Policlinico San Matteo, Division of Infectious Diseases, Department of Medical Science, Pavia, Italy

P 146 **Virological failure or transient viremia? Spontaneous resuppression in patients receiving long-acting cabotegravir/rilpivirine in the ODOACRE multicentre cohort**
L. Bortolani[1], E. Altavilla[1], V. Racolta[1], A. Ciccullo[3], G. Baldin[2], P.F. Salvo[2], M.V. Cossu[4], A. Giacomelli[4], A. Cervo[5], G. Madeddu[6], M. Fabiani[7], F. Lagi[8], F. Bassani[9], C. Mussini[5], S. Di Giambenedetto[2], G. d'Ettorre[1]
[1]Sapienza University of Rome, Rome, Italy, [2]Cattolica University of Rome, Rome, Italy, [3]Ospedale San Salvatore, L'Aquila, Italy, [4]Ospedale Luigi Sacco, Milano, Italy, [5]AOU di Modena, Modena, Italy, [6]AOU di Sassari, Sassari, Italy, [7]AOU Senese, Siena, Italy, [8]AOU Careggi, Firenze, Italy, [9]Nuovo Ospedale di Legnano, Legnano, Italy

Metabolic and other non-communicable diseases

P 147 **Cardiovascular Risk Stratification in a Cohort of Adolescents and Young Adults with Vertically Acquired HIV: Application of the 2025 ESC Focused Update**
M. Stracuzzi[1], F. Marinacci[1], C. Coppola[1], V. Giacomet[1,2]
[1]Pediatric Infectious Diseases, Luigi Sacco Hospital, ASST FBF SACCO, Milan, Italy, [2]Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università degli Studi di Milano, Italy

P 148 **Changes in body weight and metabolic parameters in people living with HIV starting an initial regimen with tenofovir disoproxil fumarate/lamivudine/doravirine or tenofovir alafenamide emtricitabine/ bictegravir or lamivudine/dolutegravir (WEINF Study)**
L. Calza[1], M. Giglia[1], A. Zuppiroli[1], D. Marzolla[1], D. Rigamonti[1], S. Cretella[1], I. Bon[2], P. Viale[1]
[1]Unit of Infectious Diseases, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy, [2]Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy

P 149 **Dual and triple antiretroviral therapies: the effect on gut microbiome**
C. Papalini, S. Marchianò, M. Albagini, S. Fiorucci, G. De Socio
University of Perugia, Department of Medicine and Surgery, Perugia, Italy

P 150 **Efficacy and safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in people living with HIV-1 with chronic renal disease**
L. Calza[1], M. Giglia[1], A. Zuppiroli[1], S. Babini[1], F. Baggio[1], J.M. Faiella[1], A. Alai[1], P. Viale[1]
[1]Unit of Infectious Diseases and [2]Unit of Microbiology, IRCCS S.Orsola Hospital, University of Bologna, Bologna, Italy

P 151 **Extreme cardiovascular risk and LDL-C target achievement in people with HIV**
A. Giacomelli[1,2], A.L. Ridolfo[1], L. Oreni[1], G. Carrozzo[1], M.V. Cossu[1], D. Moschese[1], G. Pozza[1], V. Iannone[1], A. Poloni[1], A.P. Maggioni[3], A. Gori[1,2,4], C. Gervasoni[1]
[1]Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy, [2]Department of Biomedical and Clinical Sciences, Università degli Studi di Milano, Milan, Italy, [3]ANMCO Research Center, Heart Care Foundation, Florence, Italy, [4]Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, Milan, Italy

P 152 **Factors associated with hepatic steatosis in people living with HIV with assessments of metabolic disorders, type of antiretroviral regimen, possible intima-media thickness and genetic predisposition**
L. Salmoni[1], S. Martini[1], A. Russo[1,2], G. Ricciardiello[1], F. Laguardia[1], M. Russo[1], M. Starace[1], C. Minichini[1], M. Pisaturo[1], N. Coppola[1]
[1]Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples, Italy, [2]Department of Life Science, Health, and Health Professions Link Campus University, Rome, Italy

P 153 **Lifestyle factors associated with overweight and obesity in people living with HIV on stable ART**
*B. Zanini[1], G. Gilberti[1], S. Marconi[1], M. Salvi[2], M. Rota[3], F. Donato[4], G. Tiecco[2], I. Scarvaglieri[2], F. Castelli[2], E. Quiros-Roldan[2] on behalf of LIFEH Collaboration Group**
[1]Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, [2]Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili General Hospital, Brescia, Italy, [3]Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, [4]Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy
*LIFEH Collaboration Group: A.M Della Vedova[1], M. Castellano[1], E. Focà[2]

P 154 **Low-level viremia is associated with incident diabetes in obese people with HIV**
L. Costacurta[1], L. Taramasso[2], E. Ricci[3], N. Squillace[4], G. Orofino[5], G.F. Pellicanò[6], G.V. De Socio[7], B. Menzaghi[8], S. Ferrara[9], P. Maggi[10], E. Pontali[11], S. Piconi[12], E. Sarchi[13], G. Madeddu[14], P. Bonfanti[4], A. Di Biagio[1,2]
[1]Department of Health's Sciences, University of Genoa, Genoa, Italy, [2]Infectious Diseases Unit, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy, [3]Fondazione ASIA Onlus, Buccinasco (MI), Italy, [4]Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, University of Milano-Bicocca, Monza, Italy, [5]Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, [6]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, AOU Policlinico G. Martino, Messina, Italy, [7]Clinic of Infectious Diseases, Department of Medicine and Surgery, University of Perugia, Italy, [8]Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy, [9]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, [10]Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy, [11]Department of Infectious Diseases, Galliera Hospital, Genoa, Italy, [12]Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, [13]Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, [14]Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, Italy

P 155 **Metabolic Changes After Switch to Long-Acting Cabotegravir/Rilpivirine: Implications for Cardiovascular Risk in PLWH**
V. Kelmendi[1], A. Carraro[1], R. Marocco[2], L. Ansaldo[2], G. Mancarella[2], M. D'Achille[2], C. Del Borgo[2], M. Lichtner[3]
[1]U.O.C Malattie Infettive, Azienda Ospedaliero-Universitaria Sant'Andrea, Sapienza Università di Roma, Italy, [2]U.O.C Malattie Infettive, Ospedale Santa Maria Goretti, Polo Pontino, Sapienza Università di Roma, Latina, Italy, [3]Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso NESMOS, Sapienza Università di Roma, Italy

P 156 **Metabolic Impact and Cardiovascular Risk after Switching to BIC/FTC/TAF vs DOR/3TC/TDF in a Real-world Cohort of Virologically Suppressed PLWH**
S. Colaiuda[1], C. De Vivo[1], G. Lenzi[1], G. Cucinotta[1], F. La Fata[1], L. Spina[1], A. Carbone[1], P.F. Salvo[1,2], F. Lombardi[1,2], G. Baldin[1,2], C. Torti[1,2], S. Di Giambenedetto[1,2]
[1]Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy, [2]Dipartimento di Scienze Mediche e Chirurgiche, UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

P 157 **Preserving Health Beyond Infection Control: Frailty, Weight, and Cognition in OPAT Patients**
B. Catania[1,2,3], G. Coniglione[4], G. Pipitone[1], G. Ciusa[1], C. Imburgia[1], M.G.L. Marsala[5], P. Scordo[4], A. Albanese[4], A. Cascio[2,3], G. Guaraldi[6], C. Iaria[1]
[1]Infectious and Tropical Diseases Unit, A.R.N.A.S. Civico-Di Cristina-Benfratelli, Palermo, Italy. [2]Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy, [3]Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy, [4]Infectious Diseases Unit, Hospital Papardo, Messina, Italy, [5]Quality and Clinical Risk Management Unit, A.R.N.A.S. Civico-Di Cristina-Benfratelli, Palermo, Italy, [6]Modena HIV Metabolic Clinic, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy

P 158 **Prevalence and Determinants of Liver Steatosis, Fibrosis, and Cardiovascular Risk in HIV-Monoinfected Patients on ART: STEAT-HIV Study**
G. Quartini[1], C. Di Giuli[1], L.M. Saraca[1], L. Capogrossi[1], E. Svizzerretto[1], G. Genga[1], G. Proietti[1], M. Cordoni[1], F. Gentili[2], P. Fiore[2], G.V.L. De Socio[3], C. Ucciferri[1,3]
[1]Infectious Disease Clinic, S. Maria Hospital Terni, Italy, [2]Hepatology, gastroenterology and digestive endoscopy structure, S. Maria Hospital Terni, University of Perugia, Italy, [3]Infectious Disease Clinic, Department of Medicine and Surgery, University of Perugia, Perugia, Italy

P 159 **Prevalence of Sexual dysfunction in Women living with HIV: results from SENSE study**
V. Brogna[1,2], M. Bani[1], D.P. Bernasconi[1], M.G. Strepparava[1], B. Menzaghi[3], T. Bini[4], S. Piconi[5], V. Rochira[6], P. Bonfanti[1,2] , N. Squillace[2]
[1]University of Milano-Bicocca, Milan, Italy, [2]Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, [3]ASST Valle Olona, Varese, Italy, [4]San Paolo Hospital, Milano, Italy
[5]"Alessandro Manzoni" Hospital, Lecco, Italy, [6]University of Modena and Reggio Emilia, Modena, Italy

P 160 **Reversibility of tubular renal damage after switching from TDF to TAF in a real-world setting: the impact of aging and baseline vulnerabilities**
M. Trizzino[1], A. Cicero[1,2], C. Gioè[1], M. Tamigio[2], L. Pipitò[1,2], C. Conti[1,2], C.V. Mazzola[1,2], A. Cascio[1,2]
[1]Infectious and Tropical Diseases Unit, Sicilian Regional Reference Center for the Fight Against AIDS, AOU Policlinico "P. Giaccone", Palermo, Italy, [2]Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy

P 161 **Sexual dysfunctions in men with HIV and Quality of Life: the results of SENSE study**
N. Squillace[1], V. Cogliandro[1], V. Brogna[1,2], D.P. Bernasconi[3], M. Bani[4], G. Lapadula[1,2], A. Soria[1], M.G. Strepparava[4,5], B. Menzaghi[6], T. Bini[7], S. Piconi[8], V. Rochira[9], P. Bonfanti[1,2]
[1]Clinic of Infectious Diseases, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, [2]University of Milano-Bicocca, Monza, Italy, [3]Bicocca Bioinformatics Biostatistics and Bioimaging Centre, University of Milano-Bicocca, Milan, Italy, [4]School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; 5. Clinical Unit "Psicologia Clinica", Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, [6]Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy, [7]Clinic of Infectious Diseases, San Paolo Hospital, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy, [8]Unit of Infectious Diseases, Alessandro Manzoni Hospital, ASST Lecco, Lecco, Italy, [9]Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

P 162 **Significant Weight Reduction and Metabolic Improvement with Tirzepatide in a Person Living with HIV on Long-Acting CAB/RPV**
S.G. Rizzello, R. Ferri, E. D'Arcangelo, K. Falasca, J. Vecchiet
Clinic of Infectious Diseases , "G. d'Annunzio" University of Chieti-Pescara, Italy

P 163 **Subclinical Atherosclerosis and Hepatic Fibrosis in People living with HIV: A Multivariable Analysis of Clinical, Metabolic, and Viro-Immunologic Factors**
M.S. Paternò Raddusa[1], S. Spampinato[2,3,4], G. Scuderi[5], B.S. Cacopardo[2,3], B.M. Celesia[2], A. Marino[2,3], G. Bruno[1], C. Giarratana[1], C. Gullotta[6], P. Fagone[5], P. Maggi[7], G. Nunnari[2,3]
[1]Gravina Hospital, Caltagirone (Catania), Italy, [2]ARNAS Garibaldi Hospital, Unit of Infectious Diseases, Catania, Italy, [3]University of Catania, Department of Clinical and Experimental Medicine, Catania, Italy, [4]University of Messina, Department of Clinical and Experimental Medicine, Messina, Italy, [5]Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy, [6]Umberto I Hospital, Siracusa, Italy, [7]University "Kore" of Enna Department of Medicine and Surgery, Enna Italy

P 164 **Switching to DTG/3TC or FTC/TAF/BIC in people living with HIV already on a stable TAF including regimen does not change weight and lipid profile**
N. Squillace[1], L. Taramasso[2], E. Ricci[3], B. Menzaghi[4], A. Gidari[5], G. Orofino[6], B.M. Celesia[7], E. Sarchi[8], S. Piconi[9], G. Pellicano'[10], G. Madeddu[11], S. Ferrara[12], L. Attala[13], A. Di Biagio[2], P. Bonfanti[1], for the CISAI Study Group
[1]Infectious Diseases Unit Fondazione IRCCS, San Gerardo dei Tintori-University of Milano-Bicocca, Monza, Italy, [2]Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy, [3]Fondazione ASIA Onlus, Buccinasco (MI), Italy, [4]Unit of Infectious Diseases, ASST della Valle Olona – Busto Arsizio (VA), Italy, [5]Department of Medicine and Surgery, Clinic of Infectious Diseases, "Santa Maria della Misericordia" Hospital, University of Perugia, Perugia, Italy, [6]Division I of Infectious and Tropical Diseases, ASL Città di Torino, Italy, [7]Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy, [8]Infectious Diseases Unit, S.Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, [9]Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy, [10]Infectious Diseases, G. Martino Hospital -University of Messina, Messina. Italy, [11]Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy, [12]Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy, [13]Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy

P 165 **The dark side of dietary supplements (DS) in people with HIV (PWH)**
F. Abrescia, A. Narducci, C. Grillo, F.R.P. Ieva, S. Ferrara, A. Vergori, S. Lo Caputo
Infectious Diseases Unit, Department of Clinical and Surgical Sciences, University of Foggia, Foggia, Italy

P 166 **UltRaSoUnd-guided evaLuAtion of Metabolic Health in a Cohort of Midlife Women with HIV: The URSULA study**
M. Poliseno[1], D. Capruzzi[1], A. Cianciaruso[1], N. Colavito[1], F. Dalitto[2], V. Giliberti[1], V. Lobalsamo[1], G. Metrangolo[1], M. Noviello[2], A. Vigna[1], M. Zarcone[3], F. Di Gennaro[1], V.O. Palmieri[2], A. Saracino[1]
[1]Clinic of Infectious Diseases, Department of Regenerative and Precision Medicine and Jonian Area (DiMePre-J), University of Bari, Bari, Italy, [2]Clinic of Internal Medicine, AOUC Policlinico di Bari, Bari, Italy, [3]Palermo and Province Cancer Registry, Clinical Epidemiology Unit with Cancer Registry, Azienda Ospedaliera-Universitaria Policlinico "Paolo Giaccone", University of Palermo, Palermo, Italy

P 167 **Vitamin D deficiency among women aged >50 years living with and without HIV: prevalence, predictors, and associations with metabolic diseases**
M. Poliseno, R. Starace, D. Capruzzi, A. Cianciaruso, N. Colavito, V. Giliberti, V. Lobalsamo, A. Vigna, G. Romita, F. Di Gennaro, A. Saracino
Clinic of Infectious Diseases, Department of Regenerative and Precision Medicine and Jonian Area (DiMePre-J), University of Bari, Bari, Italy

Pharmacology

P 168 **Comprehensive pharmacogenetic, pharmacokinetic and clinical assessment of bulevirtide in chronic hepatitis D patients**
J. Cusato[1], M. Antonucci[2], A. Palermiti[1], A. Manca[1], S. Perosino[2], F. Onelia[2], A. De Nicolò[1], C. Quarta[2], A. D'Avolio[1], S. Bonora[2], G. Di Perri[2], L. Marinaro[2]
[1]University of Turin, Turin, Italy, [2]Amedeo di Savoia Hospital, Turin, Italy

P 169 **The supplement is the culprit: a case of virological failure due to unexpected interactions**
S. Pagano, M. Maffezzoni, A. Dessilani, I. Baldisserotto, P.A. Grossi
Circolo Hospital and Macchi Foundation, Varese, Italy

PrEP

P 170 **Breaking barriers: Long-Acting Cabotegravir for HIV PrEP in an Italian adolescent**
C. Coppola[1], M. Stracuzzi[1], R. Caiazzo[1], M.S. Valentino[1], A. D'Avolio[2], D. Moschese[3], V. Giacomet[1]
[1]Pediatric Infectious Disease Unit, Luigi Sacco Hospital, University of Milan, Milan, Italy, [2]Department of Medical Sciences; University of Turin - ASL 'Città di Torino' Laboratory of Clinical Pharmacology and Pharmacogenetics; Amedeo di Savoia Hospital, Turin, Italy, [3]I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy

P 171 **Clinical and economic impact of pre-exposure prophylaxis (PrEP) for HIV prevention in Italy**
C. Bini[1], V. Mazzotta[2], S. Nozza[3], M. Paoletti[1], V. Scansetti[1], P. Sciattella[1]
[1]Economic Evaluation and HTA (EEHTA) - CEIS, Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy, [2]Clinical Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [3]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy

P 172 **Evolution of integrated HIV care: the Ferrara PrEP Center experience**
D. Segala[1,2], C. Magagnoli[1], P. Mori[2], C. Sartori[2], R. Cultrera[1,3]
[1]University of Ferrara, Ferrara, Italy, [2]Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy, [3]Azienda Unità Sanitaria Locale di Ferrara, Ferrara, Italy

P 173 **How PrEP impacts psychological, sexual, and relational well-being: a longitudinal evaluation**
G. Del Duca, A. Caioli, M. Maresca, R. Esvan, A.C. Brita, G. Micheli, G. Terracini, A. Giacinta, V. Barchi, D. Farinacci, R.J. Steiner, A. Antinori, V. Mazzotta
National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy

P 174 **Integrating Comprehensive Vaccination Strategies into PrEP Clinical Care: Real-World Data on Uptake and Barriers (2021–2026)**
A. Çekrezi[1], D. Zace[1], A. Morgante[1], R.A. Cavasio[1], N. Braccialarghe[1], F. Nina[1], L. Coppola[2], L. Campogiani[2], M. Iannetta[1,2], V. Malagnino[1,2], L. Sarmati[1,2]
[1]Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, [2]Infectious Diseases Unit, University Hospital Tor Vergata, Rome, Italy

P 175 **Nurse-led follow-up PrEP and STI clinic to address growing PrEP enrolments**
S. Venturelli[1], A. Crovetti[2], A. Bresciani[3], L. Comi[1], F. Borghi[1], E. Nespoli[4], G. Ghilardi[4], D. Ripamonti[1], F. Crippa[1]
[1]Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy, [2]Surgery Department, ASST Papa Giovanni XXIII, Bergamo, Italy, [3]Department of Corporate Management for Healthcare and Social Professions, ASST Papa Giovanni XXIII, Bergamo, Italy, [4]School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

P 176 **One-year outcomes of long-acting cabotegravir PrEP at a single Italian centre**
A.R. Raccagni[1,2], R. Lolatto[2], N. Capra[2], E. Bruzzesi[1,2], G. Loi[1], V. Lovato[2], L. Della Torre[2], M. Di Gerardo[2], R. Puzziferri[2], C. Ferri[2], A. Castagna[1,2], S. Nozza[1,2]
[1]Vita-Salute San Raffaele University, Milan, Italy, [2]IRCCS San Raffaele Scientific Institute, Milan, Italy

P 177 **Political and structural obstacles in Italy are driving the rise of PrEP sauvage?**
S. Mattioli[1], S. Cecere[1], L. Badia[2], S. Maugeri[1], P. Morabito[1], M. Degli Esposti[1], G. Spreafico[1]
[1]Plus - Rete Persone LGBT+ Sieropositive - aps, Bologna, Italy, [2]Azienda USL di Imola, Malattie Infettive, Imola, Italy

P 178 **PrEP experience from a single Piedmont Referral Medical Centre in Turin: a case of HIV seroconversion**
V. Ranotti[1], G. Maffeis[1], A. Sau[1], F. Donato[1], P. Crosasso[1], A. Lucchini[2], M. Tutone[2], M. Ferrara[3], S. Bonora[3]
[1]S.D.S Infectious Diseases Hospital Pharmacy, Amedeo di Savoia Hospital, ASL City of Turin, Turin, Italy, [2]S.D.S. Multidisciplinary Center for Sexual Health, Prevention Department, ASL City of Turin, Turin, Italy, [3]Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy

P 179 **PrEP Implementation in the Lombardy Region: coverage, adherence heterogeneity, and implications for HIV Prevention**
D. Moschese[1], S. Nozza[2], N.B. Bana[3], G. Ancona[4], D. Bernacchia[5], A. Pandolfo[6], S. Venturelli[7], E. Focà[8], C. Fornabaio[9], D. Radrizzani[10], L. Pagnucco[11], A. Muscatello[12], L. Corsico[13], G. Del Castillo[14], M. Maffeo[7,14], D. Cereda[14]
[1]ASST Fatebenefratelli Sacco, Milan, Italy, [2]Vita-Salute San Raffaele University, Milan, Italy, [3]ASST GOM Niguarda, Milan Italy, [4]ASST Santi Paolo e Carlo, Milan, Italy, [5]ASST Ovest Milanese, Legnano, Italy, [6]ASST Lecco, Lecco, Italy, [7]ASST Papa Giovanni XXIII, Bergamo, Italy, [8]ASST Spedali Civili di Brescia, Brescia, Italy, [9]ASST Cremona, [10]ASST Valle Olona, Busto Arsizio, Italy, [11]Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, [12]Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, [13]Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy, [14]Directorate General for Health – Lombardy Region, Milan, Italy

P 180 **PrEP in regional prevention plans: a missed opportunity for integration into national prevention plan**
G. Dessì[1], C. Sardu[2], E. Mura[1,3]
[1]Lila Cagliari OdV, Cagliari, Italy, [2]Dipartimento di Scienze Mediche e Sanità Pubblica, Università degli studi di Cagliari, Cagliari, Italy, [3]Dipartimento di Scienze Politiche e Sociali, Università degli Studi di Cagliari, Cagliari, Italy

P 181 **PREP users, sexually transmitted infections and vaccines: the experience of Centro IST Muggiò**
A. Ranzani[1], L. Corsico[1], V. Cogliandro[1], P. Columpsi[1], E. Pollastri[1], S. Limonta[1], N. Squillace[1], G. Lapadula[1,2], P. Bonfanti[1,2]
[1]S.C. Malattie Infettive, IRCCS San Gerardo dei Tintori, Monza, Italy, [2]Università degli Studi Milano-Bicocca, Italy

P 182 **Real-World Implementation of PrEP in Central Italy: Users' Risk Profile from a Territorial HIV Prevention Clinic**
G. Picchi[1,2], A. Emiliozzi[1], R. Preziosi[1], S. Farinelli[1], S. Necozione[2], V. Cofini[2]
[1]UOC Malattie Infettive, Ospedale S.Rosa ex Belcolle, Viterbo, Italy, [2]Dipartimento di Medicina clinica, sanità pubblica, scienze della vita e dell'ambiente, Università degli Studi dell'Aquila, L'Aquila, Italy

P 183 **Real-world pre-exposure prophylaxis (PrEP): safety, retention and sexually transmitted infections in an italian single-center cohort**
T. Asciore, R. Ferri, J. Vecchiet, K. Falasca
Clinic of Infectious Diseases, SS. Annunziata Hospital - "G. d'Annunzio" University of Chieti-Pescara, Italy

P 184 **Relational determinants of choosing the on-demand regimen in PrEP: real-world experience from a center in Southern Italy**
P. Congedo, G. Manco Cesari, G. Metrangolo, A. De Girolamo, A. Marignone, A.M. Maci
Clinic of Infectious Diseases, Vito Fazzi Hospital, Lecce, Italy

P 185 **Routine chemsex screening in HIV and PrEP care identifies distinct substance-use risk profiles: a real-world observational study**
A. Pastena[1], G. Bozzi[1], B. Mariani[1], N. Iannotti[1], V. Castelli[1], A. Maccaro[1], A. Gaviraghi[1], S. Roda[1], G. Renisi[1], M. Pernich[1], A. Muscatello[1], A. Bandera[1,2]
[1]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, [2]UniMi, Università degli Studi di Milano, Milan, Italy

P 186 **Self-perceived HIV risk is associated with higher retention in PrEP care compared with physician-driven referral: a real-world cohort study from Cotugno Hospital, Naples, 2023-2025**
F.M. Fusco[1], C. Camaioni[1], F. Borrelli[1], O. Tambaro[1], N. Sangiovanni[1], I.P. Ferrara[1], R. Falanga[1], N. Papa[2], V. Mattera[2], D. Ardolino[2], M. Spatarella[2], V. Sangiovanni[1], R. Viglietti[1]
[1]UOC Malattie Infettive dell'Immunodepresso; Ospedale "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy, [2]UOSD Farmacovigilanza; Famacia Ospedaliera, Ospedale "D. Cotugno", Azienda Ospedaliera dei Colli, Naples, Italy

P 187 **"TelePrEP": Bridging the Gap in HIV Prevention and Navigating Systemic Barriers in Italy**
L. Cosmaro[1], F. Falzetta[1], S. Penon[1], V. Walsh[1], A.R. Raccagni[2,3], C. Candela[2,3], S. Nozza[2,3]
[1]Fondazione LILA Milano ETS, Milan, Italy, [2]Vita-Salute San Raffaele University, Milan, Italy, [3]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

P 188 **Why are cisgender women not interested in PrEP? Risk perception and prevention gaps in a community-based setting**
L. Nekrasova[1], E. Caruso[1], L. Cavallero[1], D. Zagato[1], R. Repossi[1], I. Gotti[1], P. Russo[1], P. Vinti[1], D. Moschese[1,2], V. Iannone[1,2], R. Rossotti[1,3], M. Cernuschi[1,4], N. Frattini[1]
[1]Milano Checkpoint ETS, Milan, Italy, [2]ASST Fatebenefratelli-Sacco, Milan, Italy, [3]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [4]San Raffaele Scientific Institute, Milan, Italy

Reservoir/Cure

P 189 **One year-change in total proviral HIV-DNA in a cohort of virologically suppressed people with HIV switching to long-acting cabotegravir/rilpivirine**
A. Borghetti[1,2], F. Saladini[3], M. Fabbiani[3,4], A. Palomba[1,2], L. Fiaschi[3], M. Sambo[3,4], M. Maccarrone[2], N. Bartolini[3], E. Morelli[3,4], L. Del Bono[1,2], L. Di Gasparro[3,4], R. Iapoce[1,2], M. Falcone[1,2]
[1]Infectious Diseases Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, [2]Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, [3]Department of Medical Biotechnologies, University of Siena, Siena, Italy, [4]Infectious and Tropical Diseases Unit, Azienda Ospedaliero-Universitaria Senese, Siena, Italy

P 190 **Persistent APOBEC activity in children with longstanding HIV infection: characterization and correlation with clinical outcome**
L. Colagrossi[1], C. Dell'Angelo[2], C. Artini[2], R. Scutari[2], G. Lorenzetti[3], V. Fini[1], V. Fox[2], V.C. Di Maio[1], L. Coltella[1], S. Ranno[1], G. Linardos[1], L. Gentile[1], C. Russo[1], S. Bernardi[2], C.F. Perno[1]
[1]Microbiology and Diagnostic Immunology Unit, Bambino Gesù Children's Hospital, IRCCS; Rome, Italy, [2]Unit of Immune and Infectious Disease, University Department of Pediatrics DPUO, Bambino Gesù Children's Hospital, Rome, Italy, [3]Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS, Rome, Italy

P 191 **Reservoir persistence measured as unintegrated HIV-DNA in a real-world cohort of people living with HIV**

C. Orlandi[1,2], B. Canovari[3], F. Barchiesi[3,4], M. Magnani[5], M.B.L. Rocchi[6], A. De Maria[7,8], A. Casabianca[2,9]
[1]Department of Biomolecular Sciences, Section of Biochemistry and Biotechnology, University of Urbino Carlo Bo, Fano (PU), Italy, [2]Laboratorio Covid, University of Urbino Carlo Bo, Fano (PU), Italy, [3]Unit of Infection Diseases, San Salvatore Hospital, AST Pesaro Urbino, Pesaro, Italy, [4]Department of Biomedical Sciences and Public Health, Marche Polytechnic University (UNIVPM), Ancona, Italy, [5]Department of Biomolecular Sciences, Campus Scientifico Enrico Mattei, University of Urbino Carlo Bo, Urbino, Italy, [6]Department of Biomolecular Sciences, Service of Biostatistics, University of Urbino Carlo Bo, Urbino, Italy, [7]Department of Health Sciences, University of Genova, Genova, Italy, [8]S. C. Malattie Infettive, Azienda Sociosanitaria del Levante n. 5, Regione Liguria, Sarzana (SP), Italy, [9]Department of Pure and Applied Sciences, Section of Chemistry, Environment, and Materials, University of Urbino Carlo Bo, Urbino, Italy

STI

P 192 **Acceptability and validity of HR-HPV anal self-sampling for anal cancer screening**

E.N. Cavallari[1], M.A. Zingaropoli[2], A. Lazzaro[1], L. Bortolani[3], G.B. Tassone[4], M. Ridolfi[1], F. Alessi[1], Xh. Xhuli[4], C.M. Mastroianni[3], O. Turriziani[4], G. d'Ettorre[3]
[1]Department of Infectious Diseases, AOU Policlinico Umberto I, Rome, Italy, [2]Department of Microbiology, AOU Policlinico Umberto I, Rome, Italy, [3]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [4]Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

P 193 **Acute cholestatic hepatitis as the first manifestation of secondary syphilis in a patient living with HIV and psoriasis: a diagnostic challenge**

L. Pisano[1], M. Turco[2], J. Farini[2], A.L. Rapaccini[1]
[1]Centro MTS, S.C. Dermatologia, Ospedale Piero Palagi, Firenze, Italy, [2]Università degli Studi di Firenze, Firenze, Italy

P 194 **Adapting outreach strategies to improve access for vulnerable populations: the experience of a community-based HIV screening service in Northwest Italy**

L. Ferrari[1,5], A. Ferrari[1,3], I. Schenone[1,2], G. Notore[1,4], G. Manzi[1,4], A. Amoretti[1,4], F. Cucchetti[1,4], F. Tatta[1,4], F. Fadda[1,4], E. Pontali[1,5]
[1]ANLAIDS Sezione Liguria, Genoa, Italy, [2]IRCCS AOM Ospedale Policlinico San Martino, Genoa, Italy, [3]University of Antwerp, Antwerp, Belgium, [4]University of Genoa, Genoa, Italy, [5]Ente Ospedaliero Ospedali Galliera, Genoa, Italy

P 195 **Anal HPV persistence in an Italian cohort of people with HIV: risk factors and clinical implications**

D. Leoni[1], B. Bragato[1], A. De Rossi[2], E. Vania[1], A. Ferrari[1], E. Franchin[3], S. Gardin[1], S. Cavinato[1], L. Sasset[1], A. Cattelan[1]
[1]Azienda Ospedaliera Università di Padova - UOC Malattie Infettive e Tropicali, Padua, Italy, [2]Azienda Ospedaliera Università di Padova - UOC Psichiatria Clinica, Padua, Italy, [3]Azienda Ospedaliera Università di Padova - UOC Microbiologia e Virologia, Padua, Italy

P 196 **Assessing the risk factors for sexually transmitted infections among cisgender women in Italy. Insights from the WomanIST study and implications for prevention**

G. Canavesi[1], M. Rigoni[1,2], L. Pezzati[1], M. Ticozzelli[1,2], M.P. Bissanti[1,2], A. M. Tshishimbi[1,2], S. Rusconi[1,2]
[1]SC Malattie Infettive, ASST Ovest Milanese, Legnano (MI), Italy, [2]DIBIC, University of Milan, Italy

P 197 **Barriers to HIV prevention in adolescents: a case series and the pivotal role of specialized pediatric STI clinics**

C. Coppola[1], M. Stracuzzi[1], R. Caiazzo[1], M.S. Valentino[1], D. Moschese[2], V. Giacomet[1]
[1]Pediatric Infectious Disease Unit, Luigi Sacco Hospital, University of Milan, Milan, Italy, [2]I Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy

P 198 **Bridging the Gap in STIs Prevention. Missed Opportunities in HIV and STIs Screening in Cisgender Women: insights from the WomanIST Cohort**

M. Rigoni[1,2], G. Canavesi[1], L. Pezzati[1], M. Ticozzelli[1,2], M.P. Bissanti[1,2], A.M. Tshishimbi[1,2], D. Bernacchia[1], S. Rusconi[1,2]
[1]SC Malattie Infettive, ASST Ovest Milanese, Legnano, Italy, [2]DIBIC, University of Milan, Milan, Italy

P 199 **Burden of non-16/18 high-risk HPV and multiple-genotype infections across anal cytology grades in men living with HIV**

L. Nekrasova[1,4], F. Mazza[1], E. Ottaviano[1,4], V. Costabile[4], D. Tesoro[2], S. Ferla[1], F. Rabacchi[1], S. Ciaburri[1], P. Vella[1], D. Campisi[1], U. Gianelli[3,4], G. Marchetti[2,4], E. Borghi[1,4], C. Tincati[2,4]
[1]Microbiology and Virology Unit, ASST Santi Paolo e Carlo, Milan, Italy, [2]Clinic of Infectious Diseases, Department of Health Science, ASST Santi Paolo e Carlo, Milan, Italy, [3]Anatomical Pathology Unit, ASST Santi Paolo e Carlo, Milan, Italy, [4]Università degli Studi di Milano, Milan, Italy

P 200 **Clinical and virologic features of the novel mpox virus clade Ib identified in Milan, Italy**

D. Maddalena, F. Caruso, F. Petri, S. Lazzarin, C. Fusetti, V. Iannone, A. Giacomelli, M.V. Cossu, A. Antinori, A. Mancon, V. Micheli, A. Lombardi, A. Dolci, A. Gori, D. Mileto, D. Moschese
University of Milan, ASST Fatebenefratelli Sacco, Milan, Italy

P 201 **DoxyPEP effectiveness: identifying dosing thresholds and high-risk contexts**

R. Rossotti[1,2], E. Caruso[2], C. Muccini[2,3], A. De Bona[2,4], D. Moschese[2,5], N. Frattini[2], D. Tesoro[2,4], A. Tavelli[6], P. Vinti[2], G. Ancona[2,4], A. d'Arminio Monforte[6], M. Cernuschi[2]
[1]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [2]Milano Checkpoint ETS, Milan, Italy, [3]San Raffaele Scientific Institute, Milan, Italy, [4]ASST Santi Paolo e Carlo, Milan, Italy, [5]ASST Fatebenefratelli-Sacco, Milan, Italy, [6]ICONA Foundation, Italy

P 202 **Effectiveness of a Structured School-Based Intervention on STI Knowledge and Risk Awareness Among Italian Adolescents**

M. Salvi[1], B. Fioretti[1], A. Boldini[2], D. Minisci[1], A. Pavesi[1], S. Rapino[1], M. Inverardi[1], C. Rossi[1], M. Calamelli[1], F.Castelli[1], E. Quiros-Roldan[1], E. Focà[1]
[1]Department of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili General Hospital, Brescia, Italy, [2]Nursing School, University of Brescia, Italy

P 203 **Evaluating the feasibility of introducing routine HPV swab screening in an HIV Outpatient Clinic**
L. Pagnucco[1], M.A. Muslimani[1,2], F. Siviero[1,2], R. Bruno[1,2], R. Gulminetti[1]
[1]Infectious Diseases Unit, Medical Department, Fondazione IRCCS Policlinico San Matteo University of Pavia, Pavia, Italy, [2]Department of Medicine, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy

P 204 **From Chemsex to a Broader Drug-Sex Landscape: Comparing Two MSM Surveys from a Rome STI/HIV Reference Center**
L. Gianserra, C. Stingone, M. Zaccarelli, M.G. Dona', F. Di Tullio, E. Giuliani, M. Giuliani, A. Latini
STI/HIV Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy

P 205 **HPV vaccination coverage and prevalence of anal HPV-associated conditions in a cohort of PrEP users**
F. Ceriegi[1], S. Occhineri[1], L. del Bono[1], A. Borghetti[1], S. Ferranti[1], S. Esin[2], M. Pistello[3], C. Menconi[4], M. Falcone[1]
[1]Department of Clinical and Experimental Medicine, Infectious Disease Unit, University of Pisa, Pisa, Italy, [2]Department of Translation Medicine and New Technologies in Medicine and Surgery, Microbiology Unit, University of Pisa, Pisa, Italy, [3]Department of Translation Medicine and New Technologies in Medicine and Surgery, Virology Unit, University of Pisa, Pisa, Italy, [4]Proctology and Pelvic Floor Clinical Centre, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

P 206 **Impact of an HPV screening and treatment in a population of PrEP users - data from Perugia Hospital**
M.C. Benvenuto, S. Gobbi, G. Gonnelli, C. Papalini, G. Gamboni, C. Pallotto, A. Gidari, G.V. De Socio
Infectious Diseases Clinic, Santa Maria della Misericordia Hospital, Perugia, Italy

P 207 **Inclusive sexual health: multisectoral networks addressing STIs among vulnerable groups in Italy**
A. Chinelli[1], M. Crudele[1], V. Casigliani[1], S. Moriconi[1], F. Fortunato[2], L. Bisceglia[3], B. Suligoi[4], A. Colucci[5], V. Mazzotta[6], E. Girardi[7], D. Cereda[8], M. Maffeo[8], R. Ranieri[9], B. Pellizzari[10], G. Valdi[10], M. Ubbiali[11], M. Farinella[12], M.D. Vincenti[13], V. Vitale[13], N. Albano[13], L. Tavoschi[1], D. Martinelli[2]
[1]Department of Translational Research and New Medical and Surgical Technologies, University of Pisa, Pisa, Italy, [2]Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, [3]Strategic Regional Agency for Health and Social Care of Apulia (AReSS Puglia), Bari, Italy, [4]AIDS Operations Center, Department of Infectious Diseases, Italian National Institute of Health, Rome, Italy, [5]Operational Unit of psycho-socio-behavioural Research, Communication, Traning - Department of Infectious Diseases, Italian National Institute of Health, Rome, Italy, [6]Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy, [7]Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy, [8]Department of Prevention, General Directorate of Welfare, Regione Lombardia, Milan, Italy, [9]Infectious Diseases Service, Penitentiary Health System, Saints Paul and Charles Local Health Authority, Milan, Italy, [10]Infectious Diseases Prophylaxis and Prevention Unit, Friuli Occidentale Local Health Authority (ASFO), Pordenone, Italy, [11]Department of Human Sciences, University of Verona, Verona, Italy, [12]Italian National Association for the Fight Against Aids (ANLAIDS), Rome, Italy, [13]Department of Health, Puglia Region, Bari, Italy

P 208 **Italian infectious diseases centres' practice on Mycoplasma genitalium management: results from a PrIDE network survey**
A.R. Raccagni[1,2], G. Micheli[3], R. Lolatto[1,2], E. Caruso[5], A. Cattelan[4], S. Cecere[6], F.M. Fusco[7], M. Giglia[8], L. Del Negro[9], M. Menozzi[10], E. Milano[11], M. Ridolfi[12], R. Rossotti[13], L. Taramasso[14], D. Tesoro[15], S. Venturelli[16], A. Castagna[1,2], A. Antinori[3], D. Moschese[17], V. Mazzotta[3], M. Cernuschi[5], S. Nozza[1,2]
[1]Vita-Salute San Raffaele University, Milan, Italy, [2]IRCCS San Raffaele Scientific Institute, Milan, Italy, [3]National Institute for Infectious Diseases, Lazzaro Spallanzani IRCCS, Rome, Italy, [4]University Hospital of Padova, Padua, Italy, [5]Milano Checkpoint ETS, Milan, Italy, [6]Bologna Checkpoint, Bologna, Italy, [7]D. Cotugno Hospital, Naples, Italy, [8]IRCCS Policlinico di Sant'Orsola, University of Bologna, Bologna, Italy, [9]PLUS Roma, Rome, Italy, [10]Policlinico di Modena, Modena, Italy, [11]University Hospital Polyclinic of Bari, Bari, Italy, [12]Sapienza University, Rome, Italy, [13]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [14]IRCCS Azienda Ospedaliera Metropolitana, Genova, Italy, [15]ASST Santi Paolo e Carlo, Milan, Italy, [16]ASST Papa Giovanni XXIII, Bergamo, Italy; 17 Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy

P 209 **Minimum inhibitory concentrations and antimicrobial resistance in Neisseria gonorrhoeae by DoxyPEP exposure and use frequency in Milan, Italy**
A.R. Raccagni[1,2], C. Sagramoso[1], N. Capra[2], R. Lolatto[2], D.M. Cirillo[1,2], S. Carletti[1,2], G. Loi[1], E. Bruzzesi[2], A. Castagna[1,2], S. Nozza[1,2]
[1]Vita-Salute San Raffaele University, Milan, Italy, [2]IRCCS San Raffaele Scientific Institute, Milan, Italy

P 210 **No Evidence of Rising STI Prevalence During Early PrEP Follow-up in the Italian PrIDE Cohort**
D. Moschese[1], L. Oreni[1], G. Frate[2], R. Esvan[3], A. De Bona[4], A.M. Lucchini[5], S. Lazzarin[1], A.M. Cattelan[6], V.L. Del Negro[7], S. Cerere[8], M. Marra[9], S. Venturelli[10], M. Menozzi[11], R.J. Steiner[3], M. Tutone[5], R. Rossotti[12], S. Nozza[13], M. Cernuschi[14], V. Mazzotta[3]
[1]Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy, [2]Fondazione ICONA, Milan, Italy, [3]National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy, [4]ASST Santi Paolo e Carlo, Milan, Italy, [5]ASL Città di Torino, Turin, Italy, [6]Padua University Hospital, Padua, Italy, [7]Roma Check Point, Rome, Italy, [8]PLUS aps (BLQ Checkpoint), Bologna, Italy, [9]Circolo di Cultura Omosessuale Mario Mieli, Rome, Italy, [10]ASST "Papa Giovanni XXIII", Bergamo, Italy, [11]Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, [12]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, [13]Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, [14]ASA Milano, Milan, Italy

P 211 **Orthopoxvirus clade 1b Mpox disease with concurrent herpes zoster and EBV reactivation in an immunocompetent adult**
B. Allegretti[1], M. Chiuchiarelli[2], E. Potenza[1], M.E. Varlaro[1], A. Fiore[1], L. Vahedi[1], R. Santangelo[3], L. Celani[1], M.B. Lucia[1,2], A. Cingolani[1,2], G. Scoppettuolo[2], C. Torti[1,2]
[1]Dipartimento di Sicurezza e Bioetica - Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Itally, [2]UOC Malattie Infettive - Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCSS, Roma, Italy, [3]Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli IRRCS, Roma, Italy

P 212 **Othosiphilis: a case of monolateral hearing loss with complete recovery**
R. Alpo, L. Serroni, F. Mafrica, C. Alcantarini, O. Mollaretti, G. Di Perri
Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy

P 213 **Regional surveillance of Sexually-Transmitted Infections-Lazio, 2015–2025**
M. D'Amato, A. Agresta, I. Mussetto, M.C. Fusco, V. Vantaggio, G. Pitti, R. Esvan, G. Micheli, R.J. Steiner, V. Mazzotta, A. Antinori, G. De Carli, F. Vairo
Istituto nazionale per le malattie infettive "L. Spallanzani" – IRCCS, Rome, Italy

P 214 **Syphilitic uveitis: Descriptive analysis of a case series**
A. Buzzi, A. Marino, B. Bellocchi, A. Franzò, G. Carnemolla, E. Galati, E. Pistarà, S. Spampinato, B.M. Celesia, B. Cacopardo, G. Nunnari
ARNAS Garibaldi Hospital, Unit of Infectious Diseases, Catania, Italy

P 215 **Thousand faces disease: syphilitic hepatitis in a PrEP user, a case report**
F. Siviero[1,2], L. Pagnucco[1,2], M.A. Muslimani[1,2], R. Lissandrin[1,2], R. Bruno[1,2], R. Gulminetti[1,2]
[1]Fondazione IRCCS Policlinico San Matteo, Division of Infectious Diseases, Department of Medical Science, Pavia, Italy, [2]University of Pavia, Department of Clinical-Surgical, Diagnostic, and Pediatric Sciences, Pavia, Italy

P 216 **Unshackle the patient from IV lines: single center experience of ceftriaxone outpatient therapy for neurosyphilis**
M. d'Amato[1], G. Viceconte[1], L. Cattaneo[1], A. Sardanelli[1], S. Mercinelli[1], A.R. Buonomo[1], V. Fotticchia[1], L. De Martino[2], I. Gentile[1]
[1]University of Naples "Federico II", Naples, Italy, [2]Antonio Cardarelli Hospital, Naples, Italy

P 217 **Vulnerability Factors and Infectious Disease Burden Among Transgender Women Living With HIV**
P. Pasculli[1], M.A. Zingaropoli[1], M. Antonacci[1], F. Dominelli[1], F. Ciccone[1], M. Lichtner[2], M.R. Ciardi[1], C.M. Mastroianni[1]
[1]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [2]Department of NESMOS, Sapienza University of Rome, Rome, Italy

P 218 **Who gets vaccinated for monkeypox? Behavioral predictors of uptake among MSM attending an HIV/STI reference center**
E. Giuliani, M. Zaccarelli, M.G. Donà, L. Gianserra, C. Stingone, F. Di Tullio, M. Giuliani, A. Latini
STI/HIV Unit, San Gallicano Dermatological Institute, Rome, Italy

Vaccines and Prophylaxis

P 219 **Advocating vaccines and vaccinations as an effective strategy in tackling antimicrobial resistance in Italy**
F. Salvati[1], V. Baldo[2], P. Castiglia[3], M. Falcone[4,5], G. Gabutti[6], A. Lombardi[7], G. Marchetti[1]
[1]Clinic of Infectious and Tropical Diseases, Department of Health Sciences, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy, [2]Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Padua, Italy, [3]Department of Medicine, Surgery and Pharmacy, University of Sassari, Italian Scientific Society of Hygiene, Preventive Medicine and Public Health (SItI), Sassari, Italy, [4]Infectious Diseases Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, [5]Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, [6]Italian Scientific Society of Hygiene, Preventive Medicine and Public Health (SItI), Cogorno (Ge), Adult Immunization Board (AIB), Cogorno, Italy, [7]Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

P 220 **Bictegravir/Emtricitabine/Tenofovir alafenamide as Post-Exposure Prophylaxis: adherence, effectiveness, and safety in a real-world setting**
F. Passini[1], N. Capra[2], R. Lolatto[2], A.R. Raccagni[1], T. Clemente[2], E. Bruzzesi[2], A. Danise[2], G. Catalano[1], D. Beretta[1], P. Rienzo[3], F. Furlan[3], A. Castagna[1,2], S. Nozza[1,2]
[1]Infectious Diseases Unit, Vita-Salute San Raffaele University, Milan, Italy, [2]Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy, [3]ER Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

P 221 **From exposure to prevention: appropriateness and adherence to HIV Post-Exposure Prophylaxis in a real-world setting**
M. Inverardi[1], I. Izzo[2], S. Calza[3], S. Bertoletti[1], I. Baggi[1], I. Polesini[2], D. Bonetta[2], F. Gaffurini[2], F. Castelli[1], E. Quiros Roldan[1], E. Focà[1]
[1]Department of Clinical and Experimental Sciences, Unit of Infectious Diseases, University of Brescia, Italy, [2]ASST Spedali Civili Hospital, Brescia, Italy, [3]Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

P 222 **HPV and youth: results from the validated "HPV Survey for Young People" questionnaire (HPVSYP)**
C. Minet[1], E. Furia[1], D. Panatto[1], M. Martini[1], R. Rosselli[2], G. Icardi[1], A. Orsi[1]
[1]Department of Health Sciences, University of Genoa, Genoa, Italy, [2]Liguria Health Protection Agency, ATS - ASL 3 Genoa, Genoa, Italy

P 223 **HPV vaccination among MSM: coverage and determinants of hesitancy in PrEP users versus People Living with HIV**
M. Poliseno, A.I. Ritacco, E. Milano, L. De Santis, A. Cianciaruso, N. Colavito, F. Di Gennaro, A. Saracino
Clinic of Infectious Diseases, Department of Regenerative and Precision Medicine and Jonian Area (DiMePre-J), University of Bari, Bari, Italy

P 224 **Immunogenicity of anti-RSV vaccine 2 months and 1 year after the administration in chronic kidney disease patients**
M. Tarkowski[1], R. Gingis[2], S. Hussain[1], G. Lipari[3], A. Gabrieli[1], V. Fatizzo[3], M.A. Gallieni[1], A. Riva[1]
[1]Università degli Studi di Milano - Milan, Italy, [2]San Carlo Hospital - Milan, Italy, [3]ASST-FBF-Sacco Hospital - Milan, Italy

P 225 **Imported infectious diseases and low pre-travel awareness: observational data from a direct-access post-travel clinic**
C. Palazzolo[1], S. Vita[2], A. Cavasio[1], A. D'Abramo[1], L. Scorzolini[1], A. Curtolo[1], N. Bevilacqua[1], F. Faraglia[1], E. Nicastri[1]
[1]National Institute for Infectious Diseases Lazzaro Spallanzani IRCSS Rome, Italy, [2]Department of Neuroscience, Mental Health, and Sense Organs, NESMOS, Sapienza University of Rome, Rome, Italy

P 226 **Managing biological risk incidents in Ferrara: a 6-year analysis of PEP, clinical protocols and training needs**
D. Segala[1,2], L. Belfi[1], P. Mori[2], C. Sartori[2], R. Cultrera[1,3]
[1]University of Ferrara, Ferrara, Italy, [2]Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy, [3]Azienda Unità Sanitaria Locale di Ferrara, Ferrara, Italy

P 227 **On-site vaccination in an HIV outpatient clinic: uptake and outcomes of an integrated weekly service**
G. Orofino[1], A. Montalbano[2], M. Guastavigna[1], M. Barbaro[1], G. Milone[1], A. Ndabagiriye[1], V. Ranotti[3], G. Calleri[1]
[1]Tropical and Infectious Diseases Division A, Amedeo di Savoia Hospital, Turin, Italy, [2]Medical Science Department, University of Turin, Turin, Italy, [3]Hospital Pharmacy, Amedeo di Savoia Hospital, Turin, Italy

P 228 **Persistent failure of HBV-specific cell-mediated immunity and T-cell differentiation skewing in young PLWH despite long-term ART-induced viral suppression**
M. Stracuzzi[1], C. Vanetti[3], F. Musto[1], F. Marinacci[1], C. Coppola[1], L. De Luca[2], A. Fratta[4], M. Graziano[3], D. Trabattoni[3], V. Giacomet[1]
[1]Pediatric Infectious Diseases, Luigi Sacco Hospital, ASST FBF SACCO, Milan, Italy, [2]Dipartimento di Scienze Biomediche e Cliniche "Luigi Sacco", Università degli Studi di Milano, Italy, [3]Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, [4]Università degli Studi di Milano-Bicocca, Milan, Italy

P 229 **Zero risk of HIV transmission after percutaneous exposure to sources living with HIV with undetectable viral load**
S. Rapino, S. Arsuffi, I. Izzo, S. Bertoletti, I. Baggi, I. Polesini, F. Gaffurini, G. Tiecco, F. Castelli, E. Quiros-Roldan, E. Focà
Clinica di Malattie Infettive e Tropicali, Università degli Studi di Brescia e ASST Spedali Civili di Brescia, Italy

Virology

P 230 **Antiviral activity of microbial metabolites monensin and brefeldin A against Toscana virus and Bovine viral diarrhoea virus: in vitro evaluation and mechanistic insights**
L. Di Clemente[1], M. Acunzo[1], C. Capasso[1], P. Parimal[1], A. Chianese[1,2], R. Giugliano[1,3], C. Zannella[1], A. De Filippis[1], M. Galdiero[1,4]
[1]Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy, [2]Department of Life Sciences, Health and Health Professions, Link Campus University, 00165 Rome, Italy, [3]Department of Veterinary Medicine and Animal Production, University of Naples Federico II, Naples, Italy, [4]UOC Virology and Microbiology, University Hospital "Luigi Vanvitelli", Naples, Italy

P 231 **Broad genetic diversity of HDV and high prevalence of active HDV infection in Cameroon: insights from molecular diagnostics and whole-genome sequencing**
L. Piermatteo[1], E.L. Lebomo Etogo[2], C. Lobe[3], A. Magnapera[1], L. Carioti[4], L. Fabeni[5], G. Torre[1], I. Grossi[1], S. D'Anna[1], G. Pascal Ngaba[6], E. Enjema Lyonga[2], F. Ceccherini-Silberstein[4], R. Salpini[1], J.N. Torimiro[7], V. Svicher[1]
[1]Department of Biology, University of Rome "Tor Vergata", Rome, Italy, [2]Department of Microbiology, Virology, Parasitology, Hematology and Infectious Diseases, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Cameroon, [3]Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundere, Cameroon, [4]Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy, [5]Laboratory of Virology and Laboratories of Biosafety, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, [6]Department of Microbiology, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Cameroon, [7]Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon

P 232 **Clinical and Virological Features of a Treatment-Naïve HIV Cohort Between 2022 and 2025: A Single-Center evaluation**
N. Randazzo[1], V. Paolozzi[2], G. Massobrio[2], L. Taramasso[1], S. Varesano[1], V. Chessa[1], M. Ogliastro[1], V. Ricucci[1], A. Di Biagio[1,2], A. Orsi[1,2], B. Bruzzone[1]
[1]IRCCS Azienda Ospedaliera Metropolitana San Martino Hospital, Genoa, Italy, [2]University of Genoa, Genoa, Italy

P 233 **Cluster of Primary HIV Infections Sustained by a multidrug-resistant CRF19_cpx in MSM in Milan**
G. Bozzi[1], V. Castelli[1], A. Pastena[1], M. Pernich[1,2], S. Uceda Renteria[1], A. Parisi[1], P. Bono[1], B. Mariani[1], A. Callegaro[1], A. Muscatello[1], A. Bandera[1,2], C. Alteri[1,2]
[1]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, [2]UNIMI Università degli Studi di Milano, Milan, Italy

P 234 **High prevalence of negative outcomes in hospitalized patients for west nile virus infection in a non-endemic area in southern Italy during the outbreak in summer 2025**
C. Cacace[1], P. Grimaldi[1], L. Alessio[1], S. De Pascalis[1], R. Raucci[3], A. Sullo[5], F.G. Numis[4], C. Sagnelli[2], M. Pisaturo[1], N. Coppola[1]
[1]Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania Luigi Vanvitelli, Naples, Italy, [2]Infectious Diseases Unit, AORN Caserta, Italy, [3]Pronto Soccorso, P.O. Moscati Aversa, Caserta, Italy, [4]UOC Medicina d'Emergenza ed Urgenza. Ospedale Santa Maria delle Grazie - ASL Napoli 2 Nord, Pozzuoli, Naples, Italy, [5]Infectious Diseases Unit, PO Nocera Inferiore, Salerno, Italy

P 235 **High- and moderate-risk conditions associated with COVID-19-related hospitalization across age groups during the omicron JN.1/KP.2 period: real-world evidence from Italian claims data**
D. Malhotra[1], F.R. Ernst[1], L. Pacelli[2], I. Zografaki[3], E. Fröling[4], E. Otte im Kampe[4], R. Sini de Almeida[5], M. Lehne[6], S. Calabria[7], M. Leogrande[7], L. Degli Esposti[7], D. Curcio[8]
[1]Pfizer Inc., New York, NY, USA, [2]Pfizer, Verona, Italy, [3]Pfizer Hellas SA, Athens, Greece, [4]Pfizer Pharma GmbH, Berlin, Germany, [5]Pfizer, São Paulo, Brazil, [6]Cytel Inc., Berlin, Germany, [7]CliCon S.r.l. Società Benefit, Bologna, Italy, [8]Pfizer Inc., Madrid, Spain

P 236 **Human endogenous retrovirus expression in peripheral blood of people with HIV in different phases of the infection and during antiretroviral treatment**
E. Lazzari[1], D. Pietrucci[2], G. Rozera[1], L. Fabeni[1], F. Smoquina[1], G. Berno[1], F. Forbici[1], V. Mazzotta[1], A. Antinori[1], G. Chillemi[1,3], F. Maggi[1], I. Abbate[1]
[1]INMI L. Spallanzani, IRCCS, Rome, Italy, [2]University of Tuscia, Viterbo, Italy, [3]University of Rome "Tor Vergata", Rome, Italy

P 237 **Ilhéus Virus Infection Induces a Golgi Stress Response in Human Cells**

L. Di Clemente[1], M. Acunzo[1], C. Capasso[1], F. Palma[1], A. Chianese[1,2], R. Giugliano[1,3], C. Zannella[1], A. De Filippis[1], M. Galdiero[1,4]
[1]Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy, [2]Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy, [3]Department of Veterinary Medicine and Animal Production, University of Naples Federico II, Naples, Italy, [4]UOC Virology and Microbiology, University Hospital "Luigi Vanvitelli", Naples, Italy

P 238 **Ion Torrent Genexus as a Fast and Reliable Solution for HIV 1 Drug Resistance Testing: Comparison with the GeneStudio S5 Workflow**

F. Smoquina[1], G. Berno[1], F. Forbici[1], A. Amendola[1], G. Sberna[1], E. Lazzari[1], I. Abbate[1], G. Rozera[1], R. Gagliardini[1], V. Mazzotta[2], A. Antinori[2], F. Maggi[1], L. Fabeni[1]
[1]Laboratory of Virology and Laboratories of Biosafety, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, [2]Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy

P 239 **Long-COVID at 5 Years: Persistent Neuroinflammation and Progressive Axonal Damage in Hospitalized Patients**

P. Pasculli[1], M.A. Zingaropoli[1,2], M. Antonacci[1], F. Dominelli[1], F. Ciccone[1], M. Lichtner[3], M.R. Ciardi[1], C.M. Mastroianni[1]
[1]Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, [2]Microbiology and Virology Unit, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy, [3]Department of NESMOS, Sapienza University of Rome, Rome, Italy

P 240 **Near full length HIV genome characterization in paired cerebrospinal fluid (CSF) and plasma samples in people with HIV (PWH) naïve to antiretrovirals**

F. Smoquina[1], Abbate[1], G. Rozera[1], G. Berno[1], F. Forbici[1], A. Amendola[1], E. Lazzari[1], V. Mazzotta[2], A. Antinori[2], C. Pinnetti[2], F. Maggi[1], L. Fabeni[1]
[1]Laboratory of Virology and Laboratories of Biosafety, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy, [2]Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, Rome, Italy

P 241 **Temporal trends of antiretroviral drug resistance mutations in HIV-1 subtypes in Sicily: analysis of data from January 2021 to December 2025**

S. Cannella[1], L. Pipitò[1], C. Mascarella[2], D. Graceffa[2], A. Cascio[1], G.M. Giammanco[1], C. Bonura[1]
[1]Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro," University of Palermo, Palermo, Italy, [2]Unit of Microbiology and Virology, P. Giaccone University Hospital of Palermo, Italy

P 242 **Too late to fix? Loss of INSTI resistance mutations following INSTI withdrawal in HTE people**

L. Pagnucco[1], R. Lolatto[2], N. Capra[2], E. Foca[t3], S. Bonora[4], A. Cervo[5], M. Fabbiani[6], G. Orofino[7], D. Armenia[8], F. Saladini[9], M. Zazzi[9], M. M. Santoro[10], A. Castagna[2], R. Gulminetti[1], PRESTIGIO Study group
[1]Medical Department, Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo University of Pavia, Pavia, Italy, [2]Unit of Infectious Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University Milan, Italy, [3]Unit of Infectious and Tropical Diseases, Department of Clinical and Experimental Sciences, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, [4]Dept of Medical Sciences, University of Torino Medical School, Torino, Italy, [5]Infectious Diseases Clinic, University Hospital of Modena, Modena, Italy, [6]Department of Medical Biotechnologies, Infectious and Tropical Diseases Unit, University Hospital of Siena, Siena, Italy, [7]Division I of Infectious and Tropical Diseases, ASL Città di Torino, Turin, Italy, [8]Departimental Faculty, Saint Camillus International University of Health Sciences, Rome, Italy, [9]Department of Medical Biotechnology, University of Siena, Siena, Italy, [10]Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy

P 243 **Virucidal Broad-Spectrum Activity of Oreochromicin-1 Against Enveloped Viruses from Distinct Viral Families**

C. Capasso[1], M. Acunzo[1], L. Di Clemente[1], B.M. Nastri[1], S. Bashir[1], M. Shoaib[1], A. Chianese[1,2], R. Giugliano[1,3], C. Zannella[1], A. De Filippis[1], M. Galdiero[1,4]
[1]Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy, [2]Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy, [3]Department of Veterinary Medicine and Animal Production, University of Naples Federico II, Naples, Italy, [4]UOC Virology and Microbiology, University Hospital "Luigi Vanvitelli", Naples, Italy

P 244 **When to suspect a 'non-neuroinvasive' West Nile virus infection in Europe: an identikit suggesting subclinical neurological involvement**

C. Fanelli[1,2,3], P. Fadda[3], R. Mastinu[3], D. Pasero[2], L. La Civita[3], I. Maida[2]
[1]Intensive Care Unit, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy, [2]Infectious Diseases Unit, Department of Medicine, Surgery, and Pharmacy, University of Sassari, Sassari, Italy, [3]San Martino Hospital, Oristano, Italy